Naloxone	B-Chemical	NOUN	B
reverses	O	VERB	B
the	O	DET	O
antihypertensive	O	ADJ	B
effect	O	NOUN	I
of	O	ADP	O
clonidine	B-Chemical	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
unanesthetized	O	ADJ	B
,	O	PUNCT	O
spontaneously	O	ADV	B
hypertensive	B-Disease	ADJ	I
rats	O	NOUN	B
the	O	DET	O
decrease	O	NOUN	B
in	O	ADP	O
blood	O	NOUN	B
pressure	O	NOUN	I
and	O	CCONJ	O
heart	O	NOUN	B
rate	O	NOUN	I
produced	O	VERB	O
by	O	ADP	O
intravenous	O	ADJ	B
clonidine	B-Chemical	NOUN	B
,	O	PUNCT	O
5	O	NUM	O
to	O	PART	O
20	O	NUM	O
micrograms	O	NOUN	B
/	O	SYM	O
kg	O	NOUN	B
,	O	PUNCT	O
was	O	AUX	O
inhibited	O	VERB	B
or	O	CCONJ	O
reversed	O	VERB	O
by	O	ADP	O
nalozone	B-Chemical	NOUN	B
,	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


In	O	ADP	O
brain	O	NOUN	B
membranes	O	NOUN	I
from	O	ADP	O
spontaneously	O	ADV	B
hypertensive	B-Disease	ADJ	O
rats	O	NOUN	B
clonidine	B-Chemical	NOUN	B
,	O	PUNCT	O
10	O	NUM	O
(-	O	PUNCT	O
8	O	NUM	O
)	O	PUNCT	O
to	O	PART	O
10	O	NUM	O
(-	O	PUNCT	O
5	O	NUM	O
)	O	PUNCT	O
M	O	NOUN	B
,	O	PUNCT	O
did	O	AUX	O
not	O	PART	O
influence	O	VERB	B
stereoselective	O	ADJ	B
binding	O	NOUN	I
of	O	ADP	O
[3H]-naloxone	B-Chemical	X	B
(	O	PUNCT	O
8	O	NUM	O
nM	O	NOUN	O
),	O	PUNCT	O
and	O	CCONJ	O
naloxone	B-Chemical	NOUN	B
,	O	PUNCT	O
10	O	NUM	O
(-	O	PUNCT	O
8	O	NUM	O
)	O	PUNCT	O
to	O	PART	O
10	O	NUM	O
(-	O	PUNCT	O
4	O	NUM	O
)	O	PUNCT	O
M	O	NOUN	B
,	O	PUNCT	O
did	O	AUX	O
not	O	PART	O
influence	O	VERB	B
clonidine	B-Chemical	NOUN	B
-	O	PUNCT	O
suppressible	O	ADJ	B
binding	O	NOUN	B
of	O	ADP	O
[3H]-dihydroergocryptine	B-Chemical	X	B
(	O	PUNCT	O
1	O	NUM	O
nM	O	NOUN	O
).	O	PUNCT	O
These	O	DET	O
findings	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
in	O	ADP	O
spontaneously	O	ADV	B
hypertensive	B-Disease	ADJ	I
rats	O	NOUN	B
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
central	O	ADJ	B
alpha	O	NOUN	I
-	O	PUNCT	O
adrenoceptor	O	NOUN	B
stimulation	O	NOUN	B
involve	O	VERB	O
activation	O	NOUN	B
of	O	ADP	O
opiate	O	ADJ	B
receptors	O	NOUN	I
.	O	PUNCT	O


As	O	ADP	O
naloxone	B-Chemical	NOUN	B
and	O	CCONJ	O
clonidine	B-Chemical	NOUN	B
do	O	AUX	O
not	O	PART	O
appear	O	VERB	O
to	O	PART	O
interact	O	VERB	B
with	O	ADP	O
the	O	DET	O
same	O	ADJ	O
receptor	O	NOUN	B
site	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
observed	O	VERB	O
functional	O	ADJ	B
antagonism	O	NOUN	B
suggests	O	VERB	O
the	O	DET	O
release	O	NOUN	B
of	O	ADP	O
an	O	DET	O
endogenous	O	ADJ	B
opiate	O	NOUN	B
by	O	ADP	O
clonidine	B-Chemical	NOUN	B
or	O	CCONJ	O
alpha-methyldopa	B-Chemical	NOUN	B


Intravenous	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
a	O	DET	O
single	O	ADJ	O
50	O	NUM	O
-	O	PUNCT	O
mg	O	NOUN	O
bolus	O	NOUN	B
of	O	ADP	O
lidocaine	B-Chemical	NOUN	B
in	O	ADP	O
a	O	DET	O
67	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
man	O	NOUN	B
resulted	O	VERB	O
in	O	ADP	O
profound	O	ADJ	O
depression	B-Disease	NOUN	B
of	O	ADP	O
the	O	DET	O
activity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
sinoatrial	O	ADJ	B
and	O	CCONJ	O
atrioventricular	O	ADJ	B
nodal	O	ADJ	I
pacemakers	O	NOUN	I
.	O	PUNCT	O


Suxamethonium	B-Chemical	NOUN	B
infusion	O	NOUN	B
rate	O	NOUN	B
and	O	CCONJ	O
observed	O	VERB	O
fasciculations	B-Disease	NOUN	B
.	O	PUNCT	O


Fasciculations	B-Disease	NOUN	B
in	O	ADP	O
six	O	NUM	O
areas	O	NOUN	O
of	O	ADP	O
the	O	DET	O
body	O	NOUN	B
were	O	AUX	O
scored	O	VERB	B
from	O	ADP	O
0	O	NUM	O
to	O	PART	O
3	O	NUM	O
and	O	CCONJ	O
summated	O	VERB	B
as	O	ADP	O
a	O	DET	O
total	O	ADJ	O
fasciculation	B-Disease	NOUN	B
score	O	NOUN	B
.	O	PUNCT	O


Fasciculations	B-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
six	O	NUM	O
areas	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
total	O	ADJ	O
fasciculation	B-Disease	NOUN	B
score	O	NOUN	B
were	O	AUX	O
related	O	VERB	O
directly	O	ADV	O
to	O	ADP	O
the	O	DET	O
rate	O	NOUN	B
of	O	ADP	O
infusion	O	NOUN	B
.	O	PUNCT	O


Galanthamine	B-Chemical	NOUN	B
hydrobromide	I-Chemical	NOUN	B
,	O	PUNCT	O
a	O	DET	O
longer	O	ADV	O
acting	O	NOUN	O
anticholinesterase	O	NOUN	B
drug	O	NOUN	O
,	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
the	O	DET	O
central	O	ADJ	B
effects	O	NOUN	I
of	O	ADP	O
scopolamine	B-Chemical	NOUN	B
(	O	PUNCT	O
Hyoscine	B-Chemical	ADJ	B
).	O	PUNCT	O
Galanthamine	B-Chemical	NOUN	B
hydrobromide	I-Chemical	NOUN	I
,	O	PUNCT	O
an	O	DET	O
anticholinesterase	O	NOUN	B
drug	O	NOUN	I
capable	O	ADJ	O
of	O	ADP	O
penetrating	O	VERB	B
the	O	DET	O
blood	O	NOUN	B
-	O	PUNCT	O
brain	O	NOUN	B
barrier	O	NOUN	O
,	O	PUNCT	O
was	O	AUX	O
used	O	VERB	O
in	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
demonstrating	O	VERB	O
central	O	ADJ	B
effects	O	NOUN	I
of	O	ADP	O
scopolamine	B-Chemical	NOUN	B
(	O	PUNCT	O
hyoscine	B-Chemical	NOUN	B
)	O	PUNCT	O
overdosage	B-Disease	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
longer	O	ADV	O
acting	O	VERB	O
than	O	ADP	O
physostigmine	B-Chemical	NOUN	B
and	O	CCONJ	O
is	O	AUX	O
used	O	VERB	O
in	O	ADP	O
anaesthesia	O	NOUN	B
to	O	PART	O
reverse	O	VERB	B
the	O	DET	O
non	O	ADV	B
-	O	PUNCT	O
depolarizing	O	VERB	B
neuromuscular	O	ADJ	B
block	O	NOUN	I
.	O	PUNCT	O


Rats	O	NOUN	B
with	O	ADP	O
lithium	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
nephropathy	B-Disease	NOUN	B
were	O	AUX	O
subjected	O	VERB	O
to	O	PART	O
high	O	ADJ	B
protein	O	NOUN	I
(	O	PUNCT	O
HP	O	NOUN	B
)	O	PUNCT	O
feeding	O	NOUN	B
,	O	PUNCT	O
uninephrectomy	O	NOUN	B
(	O	PUNCT	O
NX	O	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
a	O	DET	O
combination	O	NOUN	B
of	O	ADP	O
these	O	DET	O
,	O	PUNCT	O
in	O	ADP	O
an	O	DET	O
attempt	O	NOUN	O
to	O	PART	O
induce	O	VERB	B
glomerular	O	ADJ	B
hyperfiltration	O	NOUN	B
and	O	CCONJ	O
further	O	ADJ	O
progression	O	NOUN	B
of	O	ADP	O
renal	B-Disease	ADJ	B
failure	I-Disease	NOUN	I
.	O	PUNCT	O


Newborn	O	ADJ	B
female	O	NOUN	B
Wistar	O	PROPN	B
rats	O	NOUN	I
were	O	AUX	O
fed	O	VERB	O
a	O	DET	O
lithium	B-Chemical	NOUN	B
-	O	PUNCT	O
containing	O	VERB	B
diet	O	NOUN	B
(	O	PUNCT	O
50	O	NUM	O
mmol	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
for	O	ADP	O
8	O	NUM	O
weeks	O	NOUN	B
and	O	CCONJ	O
then	O	ADV	O
randomized	O	VERB	B
to	O	PART	O
normal	O	ADJ	B
diet	O	NOUN	I
,	O	PUNCT	O
HP	O	NOUN	B
diet	O	NOUN	O
(	O	PUNCT	O
40	O	NUM	O
vs	O	CCONJ	O
.	O	PUNCT	O


When	O	SCONJ	O
comparing	O	VERB	B
all	O	DET	O
lithium	B-Chemical	NOUN	B
treated	O	VERB	B
versus	O	CCONJ	O
non	O	ADJ	B
-	O	PUNCT	O
lithium	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
groups	O	NOUN	B
,	O	PUNCT	O
lithium	B-Chemical	NOUN	B
caused	O	VERB	O
a	O	DET	O
reduction	O	NOUN	B
in	O	ADP	O
glomerular	O	ADJ	B
filtration	O	NOUN	I
rate	O	NOUN	I
(	O	PUNCT	O
GFR	O	NOUN	B
)	O	PUNCT	O
without	O	ADP	O
significant	O	ADJ	B
changes	O	NOUN	B
in	O	ADP	O
effective	O	ADJ	B
renal	O	ADJ	B
plasma	O	NOUN	I
flow	O	NOUN	I
(	O	PUNCT	O
as	O	ADP	O
determined	O	VERB	O
by	O	ADP	O
a	O	DET	O
marker	O	NOUN	B
secreted	O	VERB	B
into	O	ADP	O
the	O	DET	O
proximal	O	ADJ	B
tubules	O	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
lithium	B-Chemical	NOUN	B
clearance	O	NOUN	B
.	O	PUNCT	O


HP	O	NOUN	B
failed	O	VERB	B
to	O	PART	O
accentuante	O	VERB	B
progression	O	NOUN	B
of	O	ADP	O
renal	B-Disease	ADJ	B
failure	I-Disease	NOUN	I
and	O	CCONJ	O
in	O	ADP	O
fact	O	NOUN	O
tended	O	VERB	O
to	O	PART	O
increase	O	VERB	B
GFR	O	NOUN	B
and	O	CCONJ	O
decrease	O	VERB	B
plasma	O	NOUN	B
creatinine	B-Chemical	NOUN	O
levels	O	NOUN	O
in	O	ADP	O
lithium	B-Chemical	NOUN	B
pretreated	O	ADJ	O
rats	O	NOUN	B
.	O	PUNCT	O


NX	O	NOUN	B
+	O	CCONJ	O
HP	O	NOUN	B
caused	O	VERB	O
a	O	DET	O
further	O	ADJ	O
rise	O	NOUN	O
in	O	ADP	O
blood	O	NOUN	B
pressure	O	NOUN	I
in	O	ADP	O
Li	B-Chemical	PROPN	B
-	O	PUNCT	O
pretreated	O	VERB	B
rats	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
model	O	NOUN	B
of	O	ADP	O
chronic	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
failure	I-Disease	NOUN	I


Treatment	O	NOUN	B
of	O	ADP	O
Crohn's	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
with	O	ADP	O
fusidic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
:	O	PUNCT	O
an	O	DET	O
antibiotic	O	NOUN	B
with	O	ADP	O
immunosuppressive	O	ADJ	B
properties	O	NOUN	B
similar	O	ADJ	O
to	O	PART	O
cyclosporin	B-Chemical	NOUN	B
.	O	PUNCT	O


Fusidic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
was	O	AUX	O
administered	O	VERB	B
orally	O	ADV	B
in	O	ADP	O
a	O	DET	O
dose	O	NOUN	B
of	O	ADP	O
500	O	NUM	O
mg	O	NOUN	O
t	O	NOUN	O
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
no	O	DET	O
serious	O	ADJ	O
clinical	O	ADJ	B
side	O	NOUN	B
effects	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
dose	O	NOUN	B
reduction	O	NOUN	B
was	O	AUX	O
required	O	VERB	O
in	O	ADP	O
two	O	NUM	O
patients	O	NOUN	B
because	O	SCONJ	O
of	O	ADP	O
nausea	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
of	O	ADP	O
this	O	DET	O
pilot	O	NOUN	B
study	O	NOUN	I
suggest	O	VERB	O
that	O	SCONJ	O
fusidic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
may	O	AUX	O
be	O	AUX	O
of	O	ADP	O
benefit	O	NOUN	B
in	O	ADP	O
selected	O	VERB	O
chronic	O	ADJ	B
active	O	ADJ	O
Crohn's	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
patients	O	NOUN	B
in	O	ADP	O
whom	O	PRON	O
conventional	O	ADJ	B
treatment	O	NOUN	B
is	O	AUX	O
ineffective	O	ADJ	B
.	O	PUNCT	O


Electrocardiographic	O	ADJ	B
evidence	O	NOUN	B
of	O	ADP	O
myocardial	B-Disease	ADJ	B
injury	I-Disease	NOUN	I
in	O	ADP	O
psychiatrically	O	ADV	B
hospitalized	O	VERB	I
cocaine	B-Chemical	NOUN	B
abusers	O	NOUN	I
.	O	PUNCT	O


Eleven	O	NOUN	O
of	O	ADP	O
the	O	DET	O
cocaine	B-Chemical	NOUN	B
abusers	O	NOUN	I
and	O	CCONJ	O
none	O	NOUN	O
of	O	ADP	O
the	O	DET	O
controls	O	NOUN	B
had	O	AUX	O
ECG	O	PROPN	B
evidence	O	NOUN	B
of	O	ADP	O
significant	O	ADJ	O
myocardial	B-Disease	ADJ	B
injury	I-Disease	NOUN	I
defined	O	VERB	O
as	O	ADP	O
myocardial	B-Disease	ADJ	B
infarction	I-Disease	NOUN	I
,	O	PUNCT	O
ischemia	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
bundle	B-Disease	VERB	B
branch	I-Disease	NOUN	I
block	I-Disease	NOUN	I


Sulpiride	B-Chemical	NOUN	B
is	O	AUX	O
a	O	DET	O
selective	O	ADJ	O
D2	O	NOUN	B
-	O	PUNCT	O
receptor	O	NOUN	B
antagonist	O	NOUN	B
with	O	ADP	O
antipsychotic	O	ADJ	B
and	O	CCONJ	O
antidepressant	B-Chemical	ADJ	B
properties	O	NOUN	B
.	O	PUNCT	O


Although	O	SCONJ	O
initially	O	ADV	O
thought	O	VERB	O
to	O	PART	O
be	O	AUX	O
free	O	ADJ	B
of	O	ADP	O
extrapyramidal	O	ADJ	B
side	O	NOUN	I
effects	O	NOUN	I
,	O	PUNCT	O
sulpiride	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
tardive	B-Disease	NOUN	B
dyskinesia	I-Disease	NOUN	O
and	O	CCONJ	O
parkinsonism	B-Disease	NOUN	B
have	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
occasionally	O	ADV	O
.	O	PUNCT	O


We	O	PRON	O
could	O	AUX	O
not	O	PART	O
find	O	VERB	O
any	O	DET	O
previous	O	ADJ	O
reports	O	NOUN	B
of	O	ADP	O
sulpiride	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
tardive	B-Disease	NOUN	B
dystonia	I-Disease	NOUN	B


During	O	ADP	O
an	O	DET	O
18	O	NUM	O
-	O	PUNCT	O
month	O	NOUN	B
period	O	NOUN	B
of	O	ADP	O
study	O	NOUN	B
41	O	NUM	O
hemodialyzed	O	ADJ	B
patients	O	NOUN	B
receiving	O	VERB	O
desferrioxamine	B-Chemical	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
-	O	SYM	O
40	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
BW	O	NOUN	B
/	O	SYM	O
3	O	NUM	O
times	O	NOUN	O
weekly	O	ADJ	B
)	O	PUNCT	O
for	O	ADP	O
the	O	DET	O
first	O	ADJ	O
time	O	NOUN	O
were	O	AUX	O
monitored	O	VERB	B
for	O	ADP	O
detection	O	NOUN	B
of	O	ADP	O
audiovisual	B-Disease	ADJ	B
toxicity	I-Disease	NOUN	B
.	O	PUNCT	O


Visual	B-Disease	ADJ	B
toxicity	I-Disease	NOUN	B
was	O	AUX	O
of	O	ADP	O
retinal	O	ADJ	B
origin	O	NOUN	B
and	O	CCONJ	O
was	O	AUX	O
characterized	O	VERB	B
by	O	ADP	O
a	O	DET	O
tritan	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
dyschromatopsy	B-Disease	NOUN	B
,	O	PUNCT	O
sometimes	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
a	B-Disease	DET	O
loss	I-Disease	NOUN	B
of	I-Disease	ADP	O
visual	I-Disease	ADJ	B
acuity	I-Disease	NOUN	I
and	O	CCONJ	O
pigmentary	B-Disease	ADJ	B
retinal	I-Disease	ADJ	I
deposits	I-Disease	NOUN	I
.	O	PUNCT	O


This	O	DET	O
toxicity	B-Disease	NOUN	B
appeared	O	VERB	O
in	O	ADP	O
patients	O	NOUN	B
receiving	O	VERB	O
the	O	DET	O
higher	O	ADJ	B
doses	O	NOUN	B
of	O	ADP	O
desferrioxamine	B-Chemical	NOUN	B
or	O	CCONJ	O
coincided	O	VERB	O
with	O	ADP	O
the	O	DET	O
normalization	O	NOUN	B
of	O	ADP	O
ferritin	O	NOUN	B
or	O	CCONJ	O
aluminium	B-Chemical	NOUN	B
serum	O	NOUN	O
levels	O	NOUN	O
.	O	PUNCT	O


Myasthenia	B-Disease	ADJ	B
gravis	I-Disease	NOUN	I
presenting	O	VERB	O
as	O	ADP	O
weakness	O	NOUN	B
after	O	ADP	O
magnesium	B-Chemical	NOUN	B
administration	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
magnesium	B-Chemical	NOUN	B
was	O	AUX	O
stopped	O	VERB	B
and	O	CCONJ	O
she	O	PRON	O
recovered	O	VERB	B
over	O	ADP	O
a	O	DET	O
few	O	ADJ	O
days	O	NOUN	B
.	O	PUNCT	O


While	O	SCONJ	O
she	O	PRON	O
was	O	AUX	O
weak	O	ADJ	B
,	O	PUNCT	O
2	O	NUM	O
-	O	PUNCT	O
Hz	O	NOUN	O
repetitive	O	ADJ	B
stimulation	O	NOUN	I
revealed	O	VERB	O
a	O	DET	O
decrement	O	NOUN	B
without	O	ADP	O
significant	O	ADJ	B
facilitation	O	NOUN	B
at	O	ADP	O
rapid	O	ADJ	O
rates	O	NOUN	B
or	O	CCONJ	O
after	O	ADP	O
exercise	O	NOUN	B
,	O	PUNCT	O
suggesting	O	VERB	O
postsynaptic	B-Disease	ADJ	B
neuromuscular	I-Disease	ADJ	I
blockade	I-Disease	NOUN	I
.	O	PUNCT	O


Although	O	SCONJ	O
paralysis	B-Disease	NOUN	B
after	O	ADP	O
magnesium	B-Chemical	NOUN	B
administration	O	NOUN	I
has	O	AUX	O
been	O	AUX	O
described	O	VERB	O
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
known	O	ADJ	O
myasthenia	B-Disease	NOUN	B
gravis	I-Disease	NOUN	I
,	O	PUNCT	O
it	O	PRON	O
has	O	AUX	O
not	O	PART	O
previously	O	ADV	O
been	O	AUX	O
reported	O	VERB	O
to	O	PART	O
be	O	AUX	O
the	O	DET	O
initial	O	ADJ	B
or	O	CCONJ	O
only	O	ADJ	O
manifestation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
disease	O	NOUN	B
.	O	PUNCT	O


Chloroacetaldehyde	B-Chemical	NOUN	B
and	O	CCONJ	O
its	O	PRON	O
contribution	O	NOUN	O
to	O	PART	O
urotoxicity	O	NOUN	B
during	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
cyclophosphamide	B-Chemical	NOUN	B
or	O	CCONJ	O
ifosfamide	B-Chemical	NOUN	B
.	O	PUNCT	O


Based	O	VERB	O
on	O	ADP	O
clinical	O	ADJ	B
data	O	NOUN	I
,	O	PUNCT	O
indicating	O	VERB	O
that	O	SCONJ	O
chloroacetaldehyde	B-Chemical	NOUN	B
(	O	PUNCT	O
CAA	B-Chemical	PROPN	B
)	O	PUNCT	O
is	O	AUX	O
an	O	DET	O
important	O	ADJ	O
metabolite	O	NOUN	B
of	O	ADP	O
oxazaphosphorine	O	ADJ	B
cytostatics	O	NOUN	I
,	O	PUNCT	O
an	O	DET	O
experimental	O	ADJ	B
study	O	NOUN	I
was	O	AUX	O
carried	O	VERB	O
out	O	ADP	O
in	O	ADP	O
order	O	NOUN	O
to	O	PART	O
elucidate	O	VERB	O
the	O	DET	O
role	O	NOUN	O
of	O	ADP	O
CAA	B-Chemical	PROPN	B
in	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
hemorrhagic	B-Disease	ADJ	B
cystitis	I-Disease	NOUN	I
.	O	PUNCT	O


When	O	SCONJ	O
instilled	O	VERB	B
directly	O	ADV	O
into	O	ADP	O
the	O	DET	O
bladder	O	NOUN	B
,	O	PUNCT	O
CAA	B-Chemical	PROPN	B
exerts	O	VERB	O
urotoxic	O	ADJ	B
effects	O	NOUN	O
,	O	PUNCT	O
it	O	PRON	O
is	O	AUX	O
,	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
susceptible	O	ADJ	B
to	O	PART	O
detoxification	O	NOUN	B
with	O	ADP	O
mesna	B-Chemical	NOUN	B


Early	O	ADJ	B
onset	O	NOUN	O
migraine	B-Disease	NOUN	B
attacks	O	NOUN	B
were	O	AUX	O
induced	O	VERB	B
by	O	ADP	O
nitroglycerin	B-Chemical	NOUN	B
in	O	ADP	O
seven	O	NUM	O
out	O	ADP	O
of	O	ADP	O
10	O	NUM	O
patients	O	NOUN	B
versus	O	CCONJ	O
no	O	DET	O
patient	O	NOUN	B
in	O	ADP	O
the	O	DET	O
placebo	O	ADJ	B
group	O	NOUN	B
.	O	PUNCT	O


No	O	DET	B
early	O	ADJ	I
onset	O	NOUN	O
migraine	B-Disease	NOUN	B
was	O	AUX	O
observed	O	VERB	B
.	O	PUNCT	O


Thus	O	ADV	O
the	O	DET	O
migraine	B-Disease	NOUN	B
-	O	PUNCT	O
inducing	O	VERB	B
effect	O	NOUN	B
of	O	ADP	O
nitroglycerin	B-Chemical	NOUN	B
seems	O	VERB	O
to	O	PART	O
depend	O	VERB	O
on	O	ADP	O
direct	O	ADJ	O
stimulation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
habitual	O	ADJ	B
site	O	NOUN	I
of	O	ADP	O
pain	B-Disease	NOUN	B
,	O	PUNCT	O
suggesting	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
frontotemporal	O	ADJ	B
region	O	NOUN	I
is	O	AUX	O
of	O	ADP	O
crucial	O	ADJ	O
importance	O	NOUN	O
in	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
a	O	DET	O
migraine	B-Disease	NOUN	B
crisis	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
the	O	DET	O
case	O	NOUN	B
of	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
who	O	PRON	O
developed	O	VERB	O
acute	O	ADJ	B
hepatitis	B-Disease	NOUN	I
with	O	ADP	O
extensive	B-Disease	ADJ	O
hepatocellular	I-Disease	NOUN	B
necrosis	I-Disease	NOUN	I
,	O	PUNCT	O
7	O	NUM	O
months	O	NOUN	B
after	O	ADP	O
the	O	DET	O
onset	O	NOUN	B
of	O	ADP	I
administration	O	NOUN	B
of	O	ADP	O
clotiazepam	B-Chemical	NOUN	B
,	O	PUNCT	O
a	O	DET	O
thienodiazepine	B-Chemical	NOUN	B
derivative	O	NOUN	O
.	O	PUNCT	O


This	O	DET	O
observation	O	NOUN	B
shows	O	VERB	O
that	O	SCONJ	O
clotiazepam	B-Chemical	NOUN	B
can	O	AUX	O
induce	O	VERB	B
acute	O	ADJ	B
hepatitis	B-Disease	NOUN	I
and	O	CCONJ	O
suggests	O	VERB	O
that	O	SCONJ	O
there	O	PRON	O
is	O	AUX	O
no	O	DET	O
cross	O	NOUN	B
hepatotoxicity	B-Disease	NOUN	I
between	O	ADP	O
clotiazepam	B-Chemical	NOUN	B
and	O	CCONJ	O
several	O	ADJ	O
benzodiazepines	B-Chemical	NOUN	B


Two	O	NUM	O
of	O	ADP	O
14	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
Cushing's	B-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
treated	O	VERB	B
on	O	ADP	O
a	O	DET	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
basis	O	NOUN	O
with	O	ADP	O
ketoconazole	B-Chemical	NOUN	B
developed	O	VERB	O
sustained	O	ADJ	B
hypertension	B-Disease	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
patient	O	NOUN	B
1	O	NUM	O
,	O	PUNCT	O
plasma	O	NOUN	B
levels	O	NOUN	B
of	O	ADP	O
deoxycorticosterone	B-Chemical	NOUN	B
and	O	CCONJ	O
11-deoxycortisol	B-Chemical	NOUN	B
were	O	AUX	O
elevated	O	ADJ	B
.	O	PUNCT	O


Our	O	PRON	O
findings	O	NOUN	B
show	O	VERB	O
that	O	SCONJ	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
treatment	O	NOUN	B
with	O	ADP	O
high	O	ADJ	B
doses	O	NOUN	I
of	O	ADP	O
ketoconazole	B-Chemical	NOUN	B
may	O	AUX	O
induce	O	VERB	B
enzyme	O	NOUN	B
blockade	O	NOUN	I
leading	O	VERB	O
to	O	PART	O
mineralocorticoid	O	NOUN	B
-	O	PUNCT	O
related	O	VERB	B
hypertension	B-Disease	NOUN	B


Induction	O	NOUN	B
of	O	ADP	O
intravascular	B-Disease	ADJ	B
coagulation	I-Disease	NOUN	I
and	O	CCONJ	O
inhibition	O	NOUN	B
of	O	ADP	O
fibrinolysis	O	NOUN	B
by	O	ADP	O
injection	O	NOUN	B
of	O	ADP	O
thrombin	O	NOUN	B
and	O	CCONJ	O
tranexamic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
(	O	PUNCT	O
AMCA	B-Chemical	PROPN	B
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
rat	O	NOUN	B
gives	O	VERB	O
rise	O	NOUN	O
to	O	PART	O
pulmonary	B-Disease	ADJ	B
and	I-Disease	CCONJ	O
renal	I-Disease	ADJ	B
insufficiency	I-Disease	NOUN	I
resembling	O	VERB	O
that	O	DET	O
occurring	O	VERB	O
after	O	ADP	O
trauma	B-Disease	NOUN	B
or	O	CCONJ	O
sepsis	B-Disease	NOUN	B
in	O	ADP	O
man	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
contents	O	NOUN	B
of	O	ADP	O
albumin	O	NOUN	B
in	O	ADP	O
the	O	DET	O
lungs	O	NOUN	B
were	O	AUX	O
not	O	PART	O
changed	O	VERB	O
,	O	PUNCT	O
indicating	O	VERB	O
that	O	SCONJ	O
Captopril	B-Chemical	NOUN	B
did	O	AUX	O
not	O	PART	O
influence	O	VERB	B
the	O	DET	O
extravasation	O	NOUN	B
of	O	ADP	O
protein	O	NOUN	B
.	O	PUNCT	O


Renal	B-Disease	ADJ	B
damage	I-Disease	NOUN	I
as	O	ADP	O
reflected	O	VERB	O
by	O	ADP	O
an	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
serum	O	NOUN	B
urea	B-Chemical	NOUN	I
and	O	CCONJ	O
in	O	ADP	O
kidney	O	NOUN	B
weight	O	NOUN	I
was	O	AUX	O
prevented	O	VERB	B
by	O	ADP	O
Captopril	B-Chemical	NOUN	B
.	O	PUNCT	O


A	O	DET	O
randomized	O	ADJ	B
comparison	O	NOUN	B
of	O	ADP	O
labetalol	B-Chemical	NOUN	B
and	O	CCONJ	O
nitroprusside	B-Chemical	NOUN	B
for	O	ADP	O
induced	O	VERB	B
hypotension	B-Disease	NOUN	B
.	O	PUNCT	O


Each	O	DET	O
patient	O	NOUN	B
was	O	AUX	O
subjected	O	VERB	O
to	O	PART	O
an	O	DET	O
identical	O	ADJ	B
anesthetic	O	ADJ	B
protocol	O	NOUN	I
and	O	CCONJ	O
similar	O	ADJ	O
drug	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
reductions	B-Disease	NOUN	B
in	I-Disease	ADP	O
mean	I-Disease	ADJ	O
arterial	I-Disease	ADJ	B
blood	I-Disease	NOUN	I
pressure	I-Disease	NOUN	I
(	O	PUNCT	O
BP	O	NOUN	B
)(	O	NOUN	O
50	O	NUM	O
to	O	PART	O
55	O	NUM	O
mmHg	O	NOUN	B
).	O	PUNCT	O
Nitroprusside	O	NOUN	B
infusion	O	NOUN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
significant	O	ADJ	B
(	O	PUNCT	O
p	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


05	O	NUM	O
)	O	PUNCT	O
increase	B-Disease	NOUN	B
in	I-Disease	ADP	O
heart	I-Disease	NOUN	B
rate	I-Disease	NOUN	I
and	I-Disease	CCONJ	O
cardiac	I-Disease	ADJ	B
output	I-Disease	NOUN	I
;	O	PUNCT	O
rebound	O	ADJ	B
hypertension	B-Disease	NOUN	B
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
three	O	NUM	O
patients	O	NOUN	B
after	O	ADP	O
discontinuation	O	NOUN	B
of	O	ADP	O
nitroprusside	B-Chemical	NOUN	B
.	O	PUNCT	O


Labetalol	B-Chemical	NOUN	B
administration	O	NOUN	B
was	O	AUX	O
not	O	PART	O
associated	O	VERB	B
with	O	ADP	I
any	O	DET	O
of	O	ADP	O
these	O	DET	O
findings	O	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
was	O	AUX	O
concluded	O	VERB	O
that	O	SCONJ	O
labetalol	B-Chemical	NOUN	B
offers	O	VERB	O
advantages	O	NOUN	O
over	O	ADP	O
nitroprusside	B-Chemical	NOUN	B


Carbamazepine	B-Chemical	NOUN	B
(	O	PUNCT	O
CBZ	B-Chemical	NOUN	B
),	O	PUNCT	O
a	O	DET	O
commonly	O	ADV	O
used	O	VERB	O
AED	O	PROPN	B
,	O	PUNCT	O
has	O	AUX	O
been	O	AUX	O
implicated	O	VERB	O
in	O	ADP	O
some	O	DET	O
clinical	O	ADJ	B
studies	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
course	O	NOUN	B
of	O	ADP	O
developing	O	VERB	O
this	O	DET	O
model	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
common	O	ADJ	O
vehicle	O	NOUN	B
,	O	PUNCT	O
propylene	B-Chemical	NOUN	B
glycol	I-Chemical	NOUN	I
,	O	PUNCT	O
by	O	ADP	O
itself	O	PRON	O
in	O	ADP	O
high	O	ADJ	B
doses	O	NOUN	I
,	O	PUNCT	O
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
exhibit	O	VERB	O
protective	O	ADJ	O
properties	O	NOUN	O
against	O	ADP	O
induced	O	VERB	B
seizures	B-Disease	NOUN	B
and	O	CCONJ	O
inhibited	O	VERB	B
weight	B-Disease	NOUN	B
gain	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
CBZ	B-Chemical	NOUN	B
levels	O	NOUN	B
measured	O	VERB	B
in	O	ADP	O
plasma	O	NOUN	B
and	O	CCONJ	O
brain	O	NOUN	B
of	O	ADP	O
these	O	DET	O
animals	O	NOUN	B
,	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
were	O	AUX	O
below	O	ADP	O
those	O	DET	O
normally	O	ADV	O
considered	O	VERB	O
protective	O	ADJ	B
.	O	PUNCT	O


In	O	ADP	O
six	O	NUM	O
conscious	O	ADJ	B
,	O	PUNCT	O
trained	O	VERB	B
dogs	O	NOUN	B
,	O	PUNCT	O
maintained	O	VERB	B
on	O	ADP	O
a	O	DET	O
normal	O	ADJ	O
sodium	B-Chemical	NOUN	B
intake	O	NOUN	I
of	O	ADP	O
2	O	NUM	O
to	O	PART	O
4	O	NUM	O
mEq	O	NOUN	B
/	O	SYM	O
kg	O	NOUN	B
/	O	PUNCT	O
day	O	NOUN	B
,	O	PUNCT	O
sympathetic	O	ADJ	B
activity	O	NOUN	I
was	O	AUX	O
assessed	O	VERB	B
as	O	ADP	O
the	O	DET	O
release	O	NOUN	B
rate	O	NOUN	B
of	O	ADP	O
norepinephrine	B-Chemical	NOUN	B
and	O	CCONJ	O
epinephrine	B-Chemical	NOUN	B
during	O	ADP	O
15	O	NUM	O
-	O	PUNCT	O
minute	O	NOUN	B
i	O	NUM	O
.	O	PUNCT	O


001	O	NUM	O
),	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
but	O	CCONJ	O
no	O	DET	O
tachycardia	B-Disease	NOUN	B
and	O	CCONJ	O
no	O	DET	O
augmentation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
norepinephrine	B-Chemical	NOUN	B
release	O	NOUN	I
rate	O	NOUN	B
(	O	PUNCT	O
up	O	ADV	O
to	O	PART	O
0	O	NUM	O
.	O	PUNCT	O


Multiple	O	ADJ	B
cytotoxic	O	ADJ	B
drug	O	NOUN	B
administration	O	NOUN	I
is	O	AUX	O
the	O	DET	O
generally	O	ADV	O
accepted	O	VERB	B
treatment	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
a	O	DET	O
high	O	ADJ	B
-	O	PUNCT	O
risk	O	NOUN	B
stage	O	NOUN	I
of	O	ADP	O
choriocarcinoma	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
multiple	O	ADJ	B
drug	O	NOUN	B
schema	O	NOUN	I
consisted	O	VERB	O
of	O	ADP	O
:	O	PUNCT	O
Etoposide	B-Chemical	NOUN	B
16	O	NUM	O
.	O	PUNCT	O


On	O	ADP	O
the	O	DET	O
first	O	ADJ	O
day	O	NOUN	B
of	O	ADP	O
the	O	DET	O
schedule	O	NOUN	B
,	O	PUNCT	O
moderate	O	ADJ	B
high	O	ADJ	O
doses	O	NOUN	B
of	O	ADP	O
Methotrexate	B-Chemical	NOUN	B
,	O	PUNCT	O
Etoposide	B-Chemical	NOUN	B
and	O	CCONJ	O
Cyclophosphamide	B-Chemical	NOUN	B
were	O	AUX	O
administered	O	VERB	B
.	O	PUNCT	O


Formation	O	NOUN	B
of	O	ADP	O
these	O	DET	O
plugs	O	NOUN	B
was	O	AUX	O
probably	O	ADV	O
due	O	ADJ	O
to	O	PART	O
extensive	O	ADJ	B
tumor	B-Disease	NOUN	B
necrosis	B-Disease	NOUN	I
at	O	ADP	O
the	O	DET	O
level	O	NOUN	B
of	O	ADP	O
the	O	DET	O
walls	O	NOUN	B
of	O	ADP	O
the	O	DET	O
major	O	ADJ	O
uterine	O	NOUN	B
veins	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
resulted	O	VERB	O
in	O	ADP	O
an	O	DET	O
open	O	ADJ	O
exchange	O	NOUN	O
of	O	ADP	O
tumor	B-Disease	NOUN	B
plugs	O	NOUN	I
to	O	PART	O
the	O	DET	O
vascular	O	ADJ	B
spaces	O	NOUN	I
;	O	PUNCT	O
decrease	O	NOUN	B
in	O	ADP	O
tumor	B-Disease	NOUN	B
tissue	O	NOUN	I
coherence	O	NOUN	I
secondary	O	ADJ	B
to	O	PART	I
chemotherapy	O	NOUN	B
may	O	AUX	O
have	O	AUX	O
further	O	ADV	O
contributed	O	VERB	O
to	O	PART	O
the	O	DET	O
formation	O	NOUN	B
of	O	ADP	O
tumor	B-Disease	NOUN	B
emboli	O	NOUN	I
.	O	PUNCT	O


Patients	O	NOUN	B
with	O	ADP	O
large	O	ADJ	O
pelvic	B-Disease	ADJ	B
tumor	I-Disease	NOUN	I


The	O	DET	O
relationship	O	NOUN	B
of	O	ADP	O
arthritis	B-Disease	NOUN	B
and	O	CCONJ	O
sexual	B-Disease	ADJ	B
dysfunction	I-Disease	NOUN	I
was	O	AUX	O
investigated	O	VERB	B
among	O	ADP	O
169	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
rheumatoid	B-Disease	ADJ	B
arthritis	I-Disease	NOUN	I
,	O	PUNCT	O
osteoarthritis	B-Disease	NOUN	B
and	O	CCONJ	O
spondyloarthropathy	B-Disease	NOUN	B
,	O	PUNCT	O
130	O	NUM	O
of	O	ADP	O
whom	O	PRON	O
were	O	AUX	O
pair	O	NOUN	B
-	O	PUNCT	O
matched	O	VERB	B
to	O	PART	O
controls	O	NOUN	B
.	O	PUNCT	O


Impotence	B-Disease	NOUN	B
was	O	AUX	O
more	O	ADV	O
common	O	ADJ	O
among	O	ADP	O
male	O	NOUN	B
patients	O	NOUN	B
than	O	ADP	O
controls	O	NOUN	B
and	O	CCONJ	O
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
co	O	ADJ	B
-	O	PUNCT	O
morbidity	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
taking	O	NOUN	O
of	O	ADP	O
methotrexate	B-Chemical	NOUN	B
.	O	PUNCT	O


Depressed	B-Disease	ADJ	B
mood	I-Disease	NOUN	I
was	O	AUX	O
more	O	ADV	O
common	O	ADJ	O
among	O	ADP	O
patients	O	NOUN	B
and	O	CCONJ	O
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
certain	O	ADJ	O
sexual	O	ADJ	B
difficulties	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
with	O	ADP	O
impotence	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
renal	B-Disease	ADJ	B
papillary	I-Disease	ADJ	I
necrosis	I-Disease	NOUN	I
was	O	AUX	O
increased	O	VERB	B
nearly	O	ADV	O
20	O	NUM	O
-	O	PUNCT	O
fold	O	NOUN	B
by	O	ADP	O
consumption	O	NOUN	B
of	O	ADP	O
phenacetin	B-Chemical	NOUN	B
,	O	PUNCT	O
which	O	DET	O
also	O	ADV	O
increased	O	VERB	B
the	O	DET	O
risk	O	NOUN	B
for	O	ADP	O
cancer	B-Disease	NOUN	B
of	I-Disease	ADP	O
the	I-Disease	DET	O
renal	I-Disease	ADJ	B
pelvis	I-Disease	NOUN	I
and	I-Disease	CCONJ	O
bladder	I-Disease	NOUN	B
but	O	CCONJ	O
not	O	PART	O
for	O	ADP	O
ureteric	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


Dapsone	B-Chemical	PROPN	B
-	O	PUNCT	O
associated	O	VERB	B
Heinz	O	NOUN	B
body	O	NOUN	O
hemolytic	B-Disease	ADJ	O
anemia	I-Disease	NOUN	B
in	O	ADP	O
a	O	DET	O
Cambodian	O	ADJ	B
woman	O	NOUN	B
with	O	ADP	O
hemoglobin	O	NOUN	B
E	O	NOUN	I
trait	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
pentose	B-Chemical	NOUN	B
phosphate	I-Chemical	NOUN	I
shunt	O	NOUN	I
activity	O	NOUN	O
of	O	ADP	O
the	O	DET	O
dapsone	B-Chemical	NOUN	B
-	O	PUNCT	O
exposed	O	VERB	B
AE	O	NOUN	B
RBCs	O	NOUN	B
was	O	AUX	O
increased	O	VERB	B
compared	O	VERB	O
to	O	PART	O
normal	O	ADJ	O
RBCs	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
pentose	B-Chemical	NOUN	B
phosphate	I-Chemical	NOUN	I
shunt	O	NOUN	I
activity	O	NOUN	O
of	O	ADP	O
the	O	DET	O
non	O	ADJ	B
-	O	PUNCT	O
dapsone	B-Chemical	NOUN	B
-	O	PUNCT	O
exposed	O	VERB	B
AE	O	NOUN	B
RBCs	O	NOUN	B
was	O	AUX	O
decreased	O	VERB	B
compared	O	VERB	O
to	O	PART	O
normal	O	ADJ	O
RBCs	O	NOUN	B
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
AE	O	NOUN	B
RBCs	O	NOUN	B
appear	O	VERB	O
to	O	PART	O
have	O	AUX	O
an	O	DET	O
increased	O	VERB	B
sensitivity	O	NOUN	B
to	O	PART	O
oxidant	O	ADJ	B
stress	O	NOUN	I
both	O	CCONJ	O
in	O	X	B
vitro	O	X	I
and	O	CCONJ	O
in	O	X	B
vivo	O	X	I
,	O	PUNCT	O
since	O	SCONJ	O
dapsone	B-Chemical	NOUN	B
does	O	AUX	O
not	O	PART	O
cause	O	VERB	O
hemolytic	B-Disease	ADJ	B
anemia	I-Disease	NOUN	B
at	O	ADP	O
this	O	DET	O
dose	O	NOUN	B
in	O	ADP	O
hematologically	O	ADV	B
normal	O	ADJ	O
individuals	O	NOUN	B
.	O	PUNCT	O


Given	O	VERB	O
the	O	DET	O
influx	O	NOUN	B
of	O	ADP	O
Southeast	O	PROPN	B
Asians	O	PROPN	B
into	O	ADP	O
the	O	DET	O
United	O	PROPN	B
States	O	PROPN	I
,	O	PUNCT	O
oxidant	O	ADJ	B
medications	O	NOUN	I
should	O	AUX	O
be	O	AUX	O
used	O	VERB	O
with	O	ADP	O
caution	O	NOUN	B
,	O	PUNCT	O
especially	O	ADV	O
if	O	SCONJ	O
an	O	DET	O
infection	B-Disease	NOUN	B


AV	B-Disease	NOUN	B
block	I-Disease	NOUN	I
,	O	PUNCT	O
severe	O	ADJ	B
hypotension	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
impairment	B-Disease	NOUN	B
of	I-Disease	ADP	O
ventricular	I-Disease	ADJ	B
function	I-Disease	NOUN	I
.	O	PUNCT	O


One	O	NUM	O
week	O	NOUN	B
prior	O	ADV	O
to	O	PART	O
admission	O	NOUN	B
a	O	DET	O
therapy	O	NOUN	B
with	O	ADP	O
standard	O	ADJ	B
doses	O	NOUN	I
of	O	ADP	O
metoprolol	B-Chemical	NOUN	B
(	O	PUNCT	O
100	O	NUM	O
mg	O	NOUN	O
t	O	NOUN	O
.	O	PUNCT	O


Analyses	O	NOUN	B
of	O	ADP	O
a	O	DET	O
blood	O	NOUN	B
sample	O	NOUN	I
revealed	O	VERB	O
unusually	O	ADV	O
high	O	ADJ	O
plasma	O	NOUN	B
concentrations	O	NOUN	B
of	O	ADP	O
metoprolol	B-Chemical	NOUN	B
(	O	PUNCT	O
greater	O	ADJ	O
than	O	ADP	O
3000	O	NUM	O
ng	O	NOUN	O
/	O	PUNCT	O
ml	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
diltiazem	B-Chemical	NOUN	B
(	O	PUNCT	O
526	O	NUM	O
ng	O	NOUN	O
/	O	PUNCT	O
ml	O	NOUN	O
).	O	PUNCT	O
The	O	DET	O
patient	O	NOUN	B
recovered	O	VERB	B
within	O	ADP	O
1	O	NUM	O
week	O	NOUN	B
following	O	VERB	O
discontinuation	O	NOUN	B
of	O	ADP	O
antianginal	O	ADJ	B
therapy	O	NOUN	I
.	O	PUNCT	O


Therefore	O	ADV	O
,	O	PUNCT	O
patients	O	NOUN	B
belonging	O	VERB	O
to	O	ADP	O
the	O	DET	O
poor	O	ADJ	B
-	O	PUNCT	O
metabolizer	O	NOUN	B
phenotype	O	NOUN	B
of	O	ADP	O
sparteine	B-Chemical	NOUN	B
/	O	SYM	O
debrisoquine	B-Chemical	NOUN	B
polymorphism	O	NOUN	B
in	O	ADP	O
drug	O	NOUN	B
metabolism	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
constitutes	O	VERB	O
6	O	NUM	O
.	O	PUNCT	O


Large	O	ADJ	O
doses	O	NOUN	B
of	O	ADP	O
triazolam	B-Chemical	NOUN	B
repeatedly	O	ADV	O
induced	O	VERB	B
brief	O	ADJ	O
episodes	O	NOUN	B
of	O	ADP	O
mania	B-Disease	NOUN	B
in	O	ADP	O
a	O	DET	O
depressed	B-Disease	ADJ	B
elderly	O	ADJ	I
woman	O	NOUN	O
.	O	PUNCT	O


Features	O	NOUN	B
of	O	ADP	O
organic	B-Disease	ADJ	B
mental	I-Disease	ADJ	I
disorder	I-Disease	NOUN	I
(	O	PUNCT	O
delirium	B-Disease	NOUN	B
)	O	PUNCT	O
were	O	AUX	O
not	O	PART	O
present	O	ADJ	O
.	O	PUNCT	O


On	O	ADP	O
the	O	DET	O
mechanisms	O	NOUN	B
of	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
tolerance	O	NOUN	B
to	O	PART	O
the	O	DET	O
muscular	B-Disease	ADJ	B
rigidity	I-Disease	NOUN	I
produced	O	VERB	O
by	O	ADP	O
morphine	B-Chemical	NOUN	B
in	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


Saline	O	NOUN	B
-	O	PUNCT	O
pretreated	O	VERB	B
controls	O	NOUN	B
given	O	VERB	O
a	O	DET	O
test	O	NOUN	B
dose	O	NOUN	I
of	O	ADP	O
morphine	B-Chemical	NOUN	B
(	O	PUNCT	O
20	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	O
i	O	X	O
.	O	PUNCT	O


Rats	O	NOUN	B
treated	O	VERB	B
for	O	ADP	O
11	O	NUM	O
days	O	NOUN	B
with	O	ADP	O
morphine	B-Chemical	NOUN	B
and	O	CCONJ	O
withdrawn	O	VERB	O
for	O	ADP	O
36	O	NUM	O
-	O	PUNCT	O
40	O	NUM	O
h	O	NOUN	O
showed	O	VERB	O
differences	O	NOUN	O
in	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
tolerance	O	NOUN	B
:	O	PUNCT	O
about	O	ADV	O
half	O	NOUN	O
of	O	ADP	O
the	O	DET	O
animals	O	NOUN	B
showed	O	VERB	O
a	O	DET	O
rigidity	B-Disease	NOUN	B
after	O	ADP	O
the	O	DET	O
test	O	NOUN	B
dose	O	NOUN	I
of	O	ADP	O
morphine	B-Chemical	NOUN	B
that	O	PRON	O
was	O	AUX	O
not	O	PART	O
significantly	O	ADV	O
less	O	ADJ	O
than	O	ADP	O
in	O	ADP	O
the	O	DET	O
controls	O	NOUN	B
and	O	CCONJ	O
were	O	AUX	O
akinetic	B-Disease	ADJ	B
(	O	PUNCT	O
A	O	DET	O
group	O	NOUN	B
).	O	PUNCT	O
The	O	DET	O
other	O	ADJ	O
rats	O	NOUN	B
showed	O	VERB	O
a	O	DET	O
strong	O	ADJ	O
decrease	O	NOUN	B
in	O	ADP	O
the	O	DET	O
rigidity	B-Disease	NOUN	B
and	O	CCONJ	O
the	O	DET	O
occurrence	O	NOUN	B
of	O	ADP	O
stereotyped	O	ADJ	B
(	O	PUNCT	I
S	O	NOUN	I
)	O	PUNCT	I
licking	O	NOUN	B
and	O	CCONJ	O
/	O	SYM	O
or	O	CCONJ	O
gnawing	O	NOUN	B
in	O	ADP	O
presence	O	NOUN	B
of	O	ADP	O
akinetic	B-Disease	ADJ	B
or	O	CCONJ	O
hyperkinetic	B-Disease	ADJ	O
(	O	PUNCT	O
K	O	NOUN	O
)	O	PUNCT	O
behaviour	O	NOUN	O
(	O	PUNCT	O
AS	O	ADJ	B
/	O	SYM	O
KS	O	NOUN	B
group	O	NOUN	B
),	O	PUNCT	O
suggesting	O	VERB	O
signs	O	NOUN	O
of	O	ADP	O
dopaminergic	O	ADJ	B
activation	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
rigidity	B-Disease	NOUN	B
was	O	AUX	O
considerably	O	ADV	O
decreased	O	VERB	B
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
after	O	ADP	O
20	O	NUM	O
days	O	NOUN	B
'	O	PART	O
treatment	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
rigidity	B-Disease	NOUN	B
,	O	PUNCT	O
which	O	DET	O
is	O	AUX	O
assumed	O	VERB	O
to	O	PART	O
be	O	AUX	O
due	O	ADJ	O
to	O	PART	O
an	O	DET	O
action	O	NOUN	B
of	O	ADP	O
morphine	B-Chemical	NOUN	B
in	O	ADP	O
the	O	DET	O
striatum	O	NOUN	B
,	O	PUNCT	O
can	O	AUX	O
be	O	AUX	O
antagonized	O	VERB	B
by	O	ADP	O
another	O	DET	O
process	O	NOUN	B
leading	O	VERB	O
to	O	PART	O
dopaminergic	O	ADJ	B
activation	O	NOUN	I
in	O	ADP	O
the	O	DET	O
striatum	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
rapid	O	ADJ	O
alternations	O	NOUN	B
of	O	ADP	O
rigidity	B-Disease	NOUN	B


Fibrous	B-Disease	ADJ	B
myopathy	I-Disease	NOUN	I
is	O	AUX	O
a	O	DET	O
common	O	ADJ	O
,	O	PUNCT	O
well	O	ADV	O
-	O	PUNCT	O
known	O	VERB	B
side	O	NOUN	B
effect	O	NOUN	I
of	O	ADP	O
repeated	O	VERB	O
pentazocine	B-Chemical	NOUN	B
injection	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
a	O	DET	O
37	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
woman	O	NOUN	B
with	O	ADP	O
documented	O	VERB	B
pentazocine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
fibrous	B-Disease	ADJ	B
myopathy	I-Disease	NOUN	I
of	O	ADP	O
triceps	O	NOUN	B
and	O	CCONJ	O
deltoid	O	ADJ	B
muscles	O	NOUN	I
bilaterally	O	ADV	B
and	O	CCONJ	O
a	O	DET	O
three	O	NUM	B
-	O	PUNCT	O
week	O	NOUN	B
history	O	NOUN	B
of	O	ADP	O
right	O	ADJ	B
wrist	O	ADJ	I
drop	O	NOUN	I
,	O	PUNCT	O
electrodiagnostic	O	ADJ	B
examination	O	NOUN	I
showed	O	VERB	O
a	O	DET	O
severe	O	ADJ	B
but	O	CCONJ	O
partial	O	ADJ	B
lesion	O	NOUN	B
of	O	ADP	O
the	O	DET	O
right	O	ADJ	B
radial	O	ADJ	I
nerve	O	NOUN	I
distal	O	ADJ	I
to	O	ADP	O
the	O	DET	O
branches	O	NOUN	B
to	O	ADP	O
the	O	DET	O
triceps	O	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
addition	O	NOUN	O
to	O	PART	O
the	O	DET	O
fibrous	B-Disease	ADJ	B
myopathy	I-Disease	NOUN	I


A	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
cryptogenic	O	ADJ	B
cirrhosis	B-Disease	NOUN	I
and	O	CCONJ	O
disseminated	O	ADJ	B
sporotrichosis	B-Disease	NOUN	B
developed	O	VERB	O
acute	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
failure	I-Disease	NOUN	I
immediately	O	ADV	O
following	O	VERB	O
the	O	DET	O
administration	O	NOUN	B
of	O	ADP	O
amphotericin	B-Chemical	NOUN	B
B	I-Chemical	NOUN	O
on	O	ADP	O
four	O	NUM	O
separate	O	ADJ	B
occasions	O	NOUN	B
.	O	PUNCT	O


Pneumonitis	O	NOUN	B
with	O	ADP	O
pleural	B-Disease	ADJ	B
and	I-Disease	CCONJ	O
pericardial	I-Disease	ADJ	B
effusion	I-Disease	NOUN	I
and	O	CCONJ	O
neuropathy	B-Disease	NOUN	B
during	O	ADP	O
amiodarone	B-Chemical	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


He	O	PRON	O
developed	O	VERB	O
pneumonitis	B-Disease	NOUN	B
,	O	PUNCT	O
pleural	B-Disease	ADJ	B
and	I-Disease	CCONJ	O
pericardial	I-Disease	ADJ	B
effusions	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
predominantly	O	ADV	O
proximal	B-Disease	ADJ	B
motor	I-Disease	NOUN	B
neuropathy	I-Disease	NOUN	I
.	O	PUNCT	O


Immediate	O	ADJ	B
but	O	CCONJ	O
gradual	O	ADJ	O
improvement	O	NOUN	B
followed	O	VERB	O
withdrawal	O	NOUN	B
of	O	ADP	I
amiodarone	B-Chemical	NOUN	B
and	O	CCONJ	O
treatment	O	NOUN	B
with	O	ADP	O
prednisolone	B-Chemical	NOUN	B
.	O	PUNCT	O


Review	O	NOUN	B
of	O	ADP	O
this	O	DET	O
and	O	CCONJ	O
previously	O	ADV	O
reported	O	VERB	O
cases	O	NOUN	B
indicates	O	VERB	O
the	O	DET	O
need	O	NOUN	O
for	O	ADP	O
early	O	ADJ	B
diagnosis	O	NOUN	I
of	O	ADP	O
amiodarone	B-Chemical	NOUN	B
pneumonitis	B-Disease	NOUN	I
,	O	PUNCT	O
immediate	O	ADJ	O
withdrawal	O	NOUN	B
of	O	ADP	I
amiodarone	B-Chemical	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
prompt	O	ADJ	B
but	O	CCONJ	O
continued	O	VERB	O
steroid	B-Chemical	NOUN	B


We	O	PRON	O
have	O	AUX	O
reported	O	VERB	O
a	O	DET	O
case	O	NOUN	B
of	O	ADP	O
acute	O	ADJ	B
oliguric	O	ADJ	I
renal	B-Disease	ADJ	I
failure	I-Disease	NOUN	I
with	O	ADP	O
hyperkalemia	B-Disease	NOUN	B
in	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
cirrhosis	B-Disease	NOUN	B
,	O	PUNCT	O
ascites	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
cor	B-Disease	NOUN	B
pulmonale	I-Disease	NOUN	I
after	O	ADP	O
indomethacin	B-Chemical	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


administration	O	NOUN	B
of	O	ADP	O
flunitrazepam	B-Chemical	NOUN	B
in	O	ADP	O
volunteers	O	NOUN	B
.	O	PUNCT	O


Dizziness	B-Disease	NOUN	B
was	O	AUX	O
less	O	ADV	O
marked	O	ADJ	O
than	O	ADP	O
sedation	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
increased	O	VERB	B
with	O	ADP	O
the	O	DET	O
dose	O	NOUN	B
.	O	PUNCT	O


injection	O	NOUN	B
of	O	ADP	O
flunitrazepam	B-Chemical	NOUN	B


Changes	O	NOUN	B
in	O	ADP	O
heart	O	NOUN	B
size	O	NOUN	I
during	O	ADP	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
timolol	B-Chemical	NOUN	B
treatment	O	NOUN	B
after	O	ADP	O
myocardial	B-Disease	ADJ	B
infarction	I-Disease	NOUN	I
.	O	PUNCT	O


These	O	DET	O
differences	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
caused	O	VERB	O
by	O	ADP	O
timolol	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
bradycardia	B-Disease	NOUN	B
and	O	CCONJ	O
a	O	DET	O
compensatory	O	ADJ	B
increase	O	NOUN	B
in	O	ADP	O
end	O	NOUN	B
-	O	PUNCT	O
diastolic	O	ADJ	B
volume	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
timolol	B-Chemical	NOUN	B
-	O	PUNCT	O
related	O	VERB	B
increase	O	NOUN	B
in	O	ADP	O
heart	O	NOUN	B
size	O	NOUN	I
was	O	AUX	O
observed	O	VERB	O
only	O	ADV	O
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
normal	O	ADJ	B
and	O	CCONJ	O
borderline	O	NOUN	B
heart	O	NOUN	I
size	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
cardiomegaly	B-Disease	NOUN	B
,	O	PUNCT	O
the	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
heart	O	NOUN	B
size	O	NOUN	I
was	O	AUX	O
similar	O	ADJ	O
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


Vitamin	B-Chemical	NOUN	B
D3	I-Chemical	NOUN	I
toxicity	B-Disease	NOUN	B
in	O	ADP	O
dairy	O	ADJ	B
cows	O	NOUN	I
.	O	PUNCT	O


Calcium	B-Chemical	NOUN	B
concentrations	O	NOUN	O
1	O	NUM	O
day	O	NOUN	B
postpartum	O	NOUN	B
were	O	AUX	O
higher	O	ADJ	O
in	O	ADP	O
cows	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
vitamin	B-Chemical	NOUN	B
D3	I-Chemical	NOUN	I
about	O	ADP	O
32	O	NUM	O
days	O	NOUN	B
prepartum	O	NOUN	B
(	O	PUNCT	O
8	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
100	O	NUM	O
ml	O	NOUN	O
).	O	PUNCT	O
of	O	ADP	O
the	O	DET	O
cows	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
vitamin	B-Chemical	NOUN	B
D3	I-Chemical	NOUN	I
showed	O	VERB	O
signs	O	NOUN	O
of	O	ADP	O
milk	B-Disease	NOUN	B
fever	I-Disease	NOUN	I
during	O	ADP	O
the	O	DET	O
peripartal	O	ADJ	B
period	O	NOUN	B
;	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
22	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
control	O	NOUN	B
cows	O	NOUN	B
developed	O	VERB	O
clinical	O	ADJ	B
signs	O	NOUN	O
of	O	ADP	O
milk	B-Disease	NOUN	B
fever	I-Disease	NOUN	I
during	O	ADP	O
this	O	DET	O
period	O	NOUN	B
.	O	PUNCT	O


Because	O	SCONJ	O
of	O	ADP	O
the	O	DET	O
extreme	O	ADJ	O
toxicity	B-Disease	NOUN	B
of	O	ADP	O
vitamin	B-Chemical	NOUN	B
D3	I-Chemical	NOUN	I
in	O	ADP	O
pregnant	O	ADJ	B
Jersey	O	PROPN	I
cows	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
low	O	ADJ	B
margin	O	NOUN	B
of	O	ADP	O
safety	O	NOUN	B
between	O	ADP	O
doses	O	NOUN	B
of	O	ADP	O
vitamin	B-Chemical	NOUN	B
D3	I-Chemical	NOUN	I
that	O	PRON	O
prevent	O	VERB	B
milk	B-Disease	NOUN	B
fever	I-Disease	NOUN	I
and	O	CCONJ	O
doses	O	NOUN	B
that	O	PRON	O
induce	O	VERB	B
milk	B-Disease	NOUN	B
fever	I-Disease	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
concluded	O	VERB	O
that	O	SCONJ	O
vitamin	B-Chemical	NOUN	B
D3	I-Chemical	NOUN	I
cannot	O	NOUN	O
be	O	AUX	O
used	O	VERB	O
practically	O	ADV	O
to	O	PART	O
prevent	O	VERB	B
milk	B-Disease	NOUN	B
fever	I-Disease	NOUN	I


The	O	DET	O
anatomical	O	ADJ	B
and	O	CCONJ	O
aetiological	O	ADJ	B
diagnoses	O	NOUN	I
of	O	ADP	O
peripheral	B-Disease	ADJ	B
nerve	I-Disease	NOUN	I
disease	I-Disease	NOUN	I
excluding	O	VERB	O
its	O	PRON	O
primary	O	ADJ	B
benign	O	ADJ	I
and	O	CCONJ	O
malignant	O	ADJ	B
disorders	O	NOUN	I
,	O	PUNCT	O
as	O	ADP	O
seen	O	VERB	O
in	O	ADP	O
358	O	NUM	O
Nigerians	O	PROPN	B
are	O	AUX	O
presented	O	VERB	O
.	O	PUNCT	O


6	O	NUM	O
%),	O	ADJ	O
accounting	O	VERB	O
for	O	ADP	O
half	O	NOUN	O
of	O	ADP	O
the	O	DET	O
cases	O	NOUN	B
with	O	ADP	O
motor	B-Disease	NOUN	B
neuropathy	I-Disease	NOUN	I
.	O	PUNCT	O


Diabetes	B-Disease	NOUN	B
mellitus	I-Disease	NOUN	I
was	O	AUX	O
the	O	DET	O
major	O	ADJ	O
cause	O	NOUN	O
of	O	ADP	O
autonomic	B-Disease	ADJ	B
neuropathy	I-Disease	NOUN	I
.	O	PUNCT	O


Isoniazid	B-Chemical	NOUN	B
was	O	AUX	O
the	O	DET	O
most	O	ADV	O
frequent	O	ADJ	B
agent	O	NOUN	B
in	O	ADP	O
drug	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
neuropathy	B-Disease	NOUN	B
.	O	PUNCT	O


5	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
all	O	DET	O
the	O	DET	O
cases	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
aetiology	O	NOUN	B
of	O	ADP	O
the	O	DET	O
neuropathy	B-Disease	NOUN	B
was	O	AUX	O
undetermined	O	ADJ	O
.	O	PUNCT	O


Some	O	DET	O
of	O	ADP	O
the	O	DET	O
factors	O	NOUN	B
related	O	ADJ	O
to	O	PART	O
the	O	DET	O
clinical	O	ADJ	B
presentation	O	NOUN	I
and	O	CCONJ	O
pathogenesis	O	NOUN	B
of	O	ADP	O
the	O	DET	O
neuropathies	B-Disease	NOUN	B


In	O	ADP	O
a	O	DET	O
6	O	NUM	O
-	O	PUNCT	O
week	O	NOUN	B
double	O	ADJ	B
-	O	PUNCT	O
blind	O	ADJ	B
parallel	O	NOUN	B
treatment	O	NOUN	I
study	O	NOUN	I
,	O	PUNCT	O
dothiepin	B-Chemical	NOUN	B
and	O	CCONJ	O
amitriptyline	B-Chemical	NOUN	B
were	O	AUX	O
compared	O	VERB	O
to	O	PART	O
placebo	O	NOUN	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
33	O	NUM	O
depressed	B-Disease	ADJ	B
outpatients	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
overall	O	ADJ	O
incidence	O	NOUN	B
of	O	ADP	O
side	O	NOUN	B
effects	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
frequency	O	NOUN	B
and	O	CCONJ	O
severity	O	NOUN	B
of	O	ADP	O
blurred	B-Disease	ADJ	B
vision	I-Disease	NOUN	I
,	O	PUNCT	O
dry	B-Disease	ADJ	B
mouth	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
drowsiness	O	NOUN	B
were	O	AUX	O
significantly	O	ADV	O
less	O	ADJ	O
with	O	ADP	O
dothiepin	B-Chemical	NOUN	B
than	O	ADP	O
with	O	ADP	O
amitriptyline	B-Chemical	NOUN	B
.	O	PUNCT	O


Behavioral	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
diazepam	B-Chemical	NOUN	B
and	O	CCONJ	O
propranolol	B-Chemical	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
panic	B-Disease	NOUN	B
disorder	I-Disease	NOUN	I
and	O	CCONJ	O
agoraphobia	B-Disease	NOUN	B
.	O	PUNCT	O


Both	O	DET	O
drugs	O	NOUN	B
impaired	B-Disease	VERB	B
immediate	I-Disease	ADJ	O
free	I-Disease	ADJ	O
recall	I-Disease	NOUN	O
but	O	CCONJ	O
the	O	DET	O
decrease	O	NOUN	B
was	O	AUX	O
greater	O	ADJ	O
for	O	ADP	O
diazepam	B-Chemical	NOUN	B
than	O	ADP	O
propranolol	B-Chemical	NOUN	B
.	O	PUNCT	O


Patients	O	NOUN	B
tapped	O	VERB	O
faster	O	ADV	O
after	O	ADP	O
propranolol	B-Chemical	NOUN	B
than	O	ADP	O
diazepam	B-Chemical	NOUN	B
and	O	CCONJ	O
they	O	PRON	O
were	O	AUX	O
more	O	ADV	O
sedated	O	ADJ	B
after	O	ADP	O
diazepam	B-Chemical	NOUN	B
than	O	ADP	O
propranolol	B-Chemical	NOUN	B
.	O	PUNCT	O


Accumulation	O	NOUN	B
of	O	ADP	O
drugs	O	NOUN	B
was	O	AUX	O
not	O	PART	O
reflected	O	VERB	O
in	O	ADP	O
prolonged	O	ADJ	B
behavioral	B-Disease	ADJ	B
impairment	I-Disease	NOUN	O


An	O	DET	O
autoradiographic	O	ADJ	B
study	O	NOUN	I
was	O	AUX	O
performed	O	VERB	O
on	O	ADP	O
male	O	ADJ	B
F	O	PROPN	B
-	O	PUNCT	O
344	O	NUM	O
rats	O	NOUN	B
fed	O	VERB	O
diet	O	NOUN	B
containing	O	VERB	O
FANFT	B-Chemical	NOUN	B
at	O	ADP	O
a	O	DET	O
level	O	NOUN	B
of	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
%	O	NOUN	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
aspirin	B-Chemical	NOUN	B
on	O	ADP	O
the	O	DET	O
increased	O	VERB	B
cell	O	NOUN	B
proliferation	O	NOUN	I
induced	O	VERB	B
by	O	ADP	O
FANFT	B-Chemical	NOUN	B
in	O	ADP	O
the	O	DET	O
forestomach	O	NOUN	B
and	O	CCONJ	O
bladder	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
forestomach	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
also	O	ADV	O
in	O	ADP	O
the	O	DET	O
liver	O	NOUN	B
,	O	PUNCT	O
aspirin	B-Chemical	NOUN	B
did	O	AUX	O
not	O	PART	O
affect	O	VERB	O
the	O	DET	O
FANFT	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
increase	O	NOUN	B
in	O	ADP	O
labeling	O	NOUN	B
index	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
present	O	ADJ	O
results	O	NOUN	B
are	O	AUX	O
consistent	O	ADJ	B
with	O	ADP	I
the	O	DET	O
carcinogenicity	O	NOUN	B
experiment	O	NOUN	B
suggesting	O	VERB	O
that	O	SCONJ	O
different	O	ADJ	O
mechanisms	O	NOUN	B
are	O	AUX	O
involved	O	VERB	O
in	O	ADP	O
FANFT	B-Chemical	NOUN	B
carcinogenesis	B-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
bladder	O	NOUN	B
and	O	CCONJ	O
forestomach	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
that	O	SCONJ	O
aspirin	B-Chemical	NOUN	B
'	O	PART	O
s	O	NOUN	O
effect	O	NOUN	B
on	O	ADP	O
FANFT	B-Chemical	NOUN	B
in	O	ADP	O
the	O	DET	O
forestomach	O	NOUN	B
is	O	AUX	O
not	O	PART	O
due	O	ADJ	O
to	O	PART	O
an	O	DET	O
irritant	O	ADJ	B
effect	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
increased	O	VERB	B
cell	O	NOUN	B
proliferation	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
magnitude	O	NOUN	B
and	O	CCONJ	O
time	O	NOUN	B
course	O	NOUN	I
of	O	ADP	O
the	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
heart	O	NOUN	B
rate	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
decrease	O	NOUN	B
in	O	ADP	O
systolic	O	ADJ	B
blood	O	NOUN	I
pressure	O	NOUN	I
after	O	ADP	O
nitroglycerin	B-Chemical	NOUN	B
were	O	AUX	O
similar	O	ADJ	O
in	O	ADP	O
the	O	DET	O
normal	O	ADJ	B
and	O	CCONJ	O
diabetic	B-Disease	ADJ	B
subjects	O	NOUN	B
without	O	ADP	O
autonomic	B-Disease	ADJ	B
neuropathy	I-Disease	NOUN	I
,	O	PUNCT	O
whereas	O	SCONJ	O
a	O	DET	O
lesser	O	ADJ	O
increase	O	NOUN	B
in	O	ADP	O
heart	O	NOUN	B
rate	O	NOUN	I
and	O	CCONJ	O
a	O	DET	O
greater	O	ADJ	O
decrease	O	NOUN	B
in	O	ADP	O
systolic	O	ADJ	B
blood	O	NOUN	I
pressure	O	NOUN	I
occurred	O	VERB	O
in	O	ADP	O
the	O	DET	O
diabetic	B-Disease	ADJ	B
subjects	O	NOUN	B
with	O	ADP	O
autonomic	B-Disease	ADJ	B
neuropathy	I-Disease	NOUN	I
.	O	PUNCT	O


Pituitary	B-Disease	ADJ	B
tumors	I-Disease	NOUN	I
were	O	AUX	O
induced	O	VERB	B
in	O	ADP	O
F344	O	NOUN	B
female	O	NOUN	O
rats	O	NOUN	B
by	O	ADP	O
chronic	O	ADJ	B
treatment	O	NOUN	I
with	O	ADP	O
diethylstilbestrol	B-Chemical	NOUN	B
(	O	PUNCT	O
DES	B-Chemical	NOUN	B
,	O	PUNCT	O
8	O	NUM	O
-	O	SYM	O
10	O	NUM	O
mg	O	NOUN	O
)	O	PUNCT	O
implanted	O	VERB	B
subcutaneously	O	ADV	B
in	O	ADP	O
silastic	O	ADJ	B
capsules	O	NOUN	I
.	O	PUNCT	O


Over	O	ADP	O
a	O	DET	O
range	O	NOUN	O
of	O	ADP	O
1	O	NUM	O
-	O	PUNCT	O
150	O	NUM	O
days	O	NOUN	B
of	O	ADP	O
DES	B-Chemical	NOUN	B
treatment	O	NOUN	B
,	O	PUNCT	O
pairs	O	NOUN	B
of	O	ADP	O
control	O	NOUN	B
and	O	CCONJ	O
DES	B-Chemical	PROPN	B
-	O	PUNCT	O
treated	O	VERB	B
rats	O	NOUN	B
were	O	AUX	O
sacrificed	O	VERB	B
,	O	PUNCT	O
and	O	CCONJ	O
their	O	PRON	O
pituitaries	O	NOUN	B
dissociated	O	VERB	O
enzymatically	O	ADV	B
into	O	ADP	O
single	O	ADJ	B
-	O	PUNCT	O
cell	O	NOUN	B
preparations	O	NOUN	B
.	O	PUNCT	O


Total	O	ADJ	B
cell	O	NOUN	I
yields	O	NOUN	O
from	O	ADP	O
DES	B-Chemical	PROPN	B
-	O	PUNCT	O
treated	O	VERB	B
pituitaries	O	NOUN	B
increased	O	VERB	B
from	O	ADP	O
1	O	NUM	O
.	O	PUNCT	O


Beyond	O	NOUN	O
8	O	NUM	O
days	O	NOUN	B
of	O	ADP	O
DES	B-Chemical	NOUN	B
exposure	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
immunochemically	O	ADV	B
PRL	O	NOUN	B
-	O	PUNCT	O
positive	O	ADJ	B
proportion	O	NOUN	B
of	O	ADP	O
cells	O	NOUN	B
increased	O	VERB	B
to	O	PART	O
over	O	ADP	O
50	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
total	O	ADJ	B
population	O	NOUN	I
.	O	PUNCT	O


Triamterene	B-Chemical	NOUN	B
nephrolithiasis	B-Disease	NOUN	I
complicating	O	VERB	O
dyazide	B-Chemical	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
stone	O	NOUN	B
passed	O	VERB	O
spontaneously	O	ADV	B
and	O	CCONJ	O
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
contain	O	VERB	O
a	O	DET	O
triamterene	B-Chemical	NOUN	B
metabolite	O	NOUN	B
admixed	O	ADJ	B
with	O	ADP	O
uric	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
salts	I-Chemical	NOUN	I
.	O	PUNCT	O


Factors	O	NOUN	B
affecting	O	VERB	O
triamterene	B-Chemical	NOUN	B
nephrolithiasis	B-Disease	NOUN	B


The	O	DET	O
cardiotoxic	B-Disease	ADJ	B
effects	O	NOUN	I
of	O	ADP	O
adriamycin	B-Chemical	NOUN	B
were	O	AUX	O
studied	O	VERB	O
in	O	ADP	O
mammalian	O	ADJ	B
myocardial	O	ADJ	B
cells	O	NOUN	I
in	O	ADP	O
culture	O	NOUN	B
as	O	ADP	O
a	O	DET	O
model	O	NOUN	B
system	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
possible	O	ADJ	O
involvement	O	NOUN	B
of	O	ADP	O
energy	O	NOUN	B
metabolism	O	NOUN	I
was	O	AUX	O
suggested	O	VERB	O
previously	O	ADV	O
,	O	PUNCT	O
and	O	CCONJ	O
in	O	ADP	O
this	O	DET	O
study	O	NOUN	B
the	O	DET	O
adenylate	O	ADJ	B
energy	O	NOUN	I
charge	O	NOUN	I
and	O	CCONJ	O
phosphorylcreatine	B-Chemical	ADJ	B
mole	O	NOUN	I
fraction	O	NOUN	O
were	O	AUX	O
determined	O	VERB	O
in	O	ADP	O
the	O	DET	O
adriamycin	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
cells	O	NOUN	B
.	O	PUNCT	O


Such	O	ADJ	O
disparity	O	NOUN	B
suggests	O	VERB	O
an	O	DET	O
inhibition	O	NOUN	B
of	O	ADP	O
creatine	B-Chemical	NOUN	B
phosphokinase	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
adriamycin	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
cells	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
addition	O	NOUN	O
of	O	ADP	O
adenosine	B-Chemical	NOUN	B


Abnormal	B-Disease	ADJ	B
movements	I-Disease	NOUN	B
and	O	CCONJ	O
deafness	B-Disease	NOUN	B
occurred	O	VERB	O
only	O	ADV	O
in	O	ADP	O
rats	O	NOUN	B
treated	O	VERB	B
during	O	ADP	O
the	O	DET	O
preweaning	O	NOUN	B
period	O	NOUN	B
;	O	PUNCT	O
within	O	ADP	O
this	O	DET	O
period	O	NOUN	B
the	O	DET	O
greatest	O	ADJ	O
sensitivities	O	NOUN	B
for	O	ADP	O
these	O	DET	O
abnormalities	O	NOUN	B
occurred	O	VERB	O
from	O	ADP	O
2	O	NUM	O
to	O	PART	O
11	O	NUM	O
-	O	SYM	O
17	O	NUM	O
and	O	CCONJ	O
5	O	NUM	O
to	O	PART	O
11	O	NUM	O
days	O	NOUN	B
of	O	ADP	O
age	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
indicating	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
cochlea	O	NOUN	B
is	O	AUX	O
more	O	ADV	O
sensitive	O	ADJ	B
to	O	PART	O
streptomycin	B-Chemical	NOUN	B
than	O	ADP	O
the	O	DET	O
site	O	NOUN	B
(	O	PUNCT	O
vestibular	O	ADJ	B
or	O	CCONJ	O
central	O	ADJ	B
)	O	PUNCT	O
responsible	O	ADJ	O
for	O	ADP	O
the	O	DET	O
dyskinesias	B-Disease	NOUN	B


This	O	DET	O
case	O	NOUN	B
study	O	NOUN	I
reveals	O	VERB	O
an	O	DET	O
unusual	O	ADJ	O
finding	O	NOUN	B
of	O	ADP	O
rapidly	O	ADV	B
proliferative	O	ADJ	B
crescentic	O	ADJ	O
glomerulonephritis	B-Disease	NOUN	O
in	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
rifampin	B-Chemical	NOUN	B
who	O	PRON	O
had	O	AUX	O
no	O	DET	O
other	O	ADJ	O
identifiable	O	ADJ	O
causes	O	NOUN	O
for	O	ADP	O
developing	O	VERB	O
this	O	DET	O
disease	O	NOUN	B
.	O	PUNCT	O


Renal	O	ADJ	B
biopsy	O	NOUN	I
revealed	O	VERB	O
severe	O	ADJ	B
glomerulonephritis	B-Disease	NOUN	B
with	O	ADP	O
crescents	O	NOUN	B
,	O	PUNCT	O
electron	O	NOUN	B
dense	O	ADJ	I
fibrillar	O	ADJ	I
deposits	O	NOUN	I
and	O	CCONJ	O
moderate	O	ADJ	B
lymphocytic	O	ADJ	B
interstitial	O	ADJ	I
infiltrate	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
report	O	NOUN	B
documents	O	VERB	I
the	O	DET	O
unusual	O	ADJ	B
occurrence	O	NOUN	B
of	O	ADP	O
rapidly	O	ADV	O
progressive	O	ADJ	B
glomerulonephritis	B-Disease	NOUN	B
with	O	ADP	O
crescents	O	NOUN	B
and	O	CCONJ	O
fibrillar	O	ADJ	B
glomerulonephritis	B-Disease	NOUN	I
in	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
rifampin	B-Chemical	NOUN	B


Reactive	O	ADJ	B
oxygen	B-Chemical	NOUN	I
species	O	NOUN	I
have	O	AUX	O
been	O	AUX	O
implicated	O	VERB	O
in	O	ADP	O
the	O	DET	O
pathogenesis	O	NOUN	B
of	O	ADP	O
acute	O	ADJ	B
puromycin	B-Chemical	NOUN	I
aminonucleoside	I-Chemical	NOUN	I
(	O	PUNCT	O
PAN	B-Chemical	NOUN	B
)-	O	ADJ	O
induced	O	VERB	B
nephropathy	B-Disease	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
antioxidants	O	NOUN	B
significantly	O	ADV	O
reducing	O	VERB	B
the	O	DET	O
proteinuria	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
temporal	O	ADJ	B
relationship	O	NOUN	B
between	O	ADP	O
lipid	O	NOUN	B
peroxidation	O	NOUN	I
in	O	ADP	O
the	O	DET	O
kidney	O	NOUN	B
and	O	CCONJ	O
proteinuria	B-Disease	NOUN	B
was	O	AUX	O
examined	O	VERB	O
in	O	ADP	O
this	O	DET	O
study	O	NOUN	B
.	O	PUNCT	O


Rats	O	NOUN	B
were	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
a	O	DET	O
single	O	ADJ	B
IV	O	NUM	I
injection	O	NOUN	B
of	O	ADP	O
puromycin	B-Chemical	NOUN	B
aminonucleoside	I-Chemical	NOUN	B
,(	O	PUNCT	O
PAN	B-Chemical	NOUN	B
,	O	PUNCT	O
7	O	NUM	O
.	O	PUNCT	O


Clomipramine	B-Chemical	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
sleep	B-Disease	NOUN	B
disturbance	I-Disease	NOUN	I
does	O	AUX	O
not	O	PART	O
impair	O	VERB	O
its	O	PRON	O
prolactin	O	NOUN	B
-	O	PUNCT	O
releasing	O	VERB	B
action	O	NOUN	B
.	O	PUNCT	O


Two	O	NUM	O
groups	O	NOUN	B
of	O	ADP	O
supine	O	ADJ	B
subjects	O	NOUN	I
were	O	AUX	O
studied	O	VERB	O
under	O	ADP	O
placebo	O	NOUN	B
-	O	PUNCT	O
controlled	O	VERB	B
conditions	O	NOUN	B
,	O	PUNCT	O
one	O	NUM	O
during	O	ADP	O
the	O	DET	O
night	O	NOUN	B
,	O	PUNCT	O
when	O	SCONJ	O
sleeping	O	VERB	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
7	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
other	O	ADJ	O
at	O	ADP	O
daytime	O	NOUN	B
,	O	PUNCT	O
when	O	SCONJ	O
awake	O	ADJ	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
6	O	NUM	O
).	O	PUNCT	O
Each	O	DET	O
subject	O	NOUN	B
received	O	VERB	O
a	O	DET	O
single	O	ADJ	O
50	O	NUM	O
mg	O	NOUN	O
dose	O	NOUN	B
of	O	ADP	O
clomipramine	B-Chemical	NOUN	B
given	O	VERB	O
orally	O	ADV	B
2	O	NUM	I
hours	O	NOUN	B
before	O	ADP	O
blood	O	NOUN	B
collection	O	NOUN	I
.	O	PUNCT	O


As	O	ADP	O
the	O	DET	O
relative	O	ADJ	O
increase	O	NOUN	B
in	O	ADP	O
PRL	O	NOUN	B
secretion	O	NOUN	B
expressed	O	VERB	B
as	O	ADP	O
a	O	DET	O
percentage	O	NOUN	B
of	O	ADP	O
the	O	DET	O
mean	O	NOUN	O
did	O	AUX	O
not	O	PART	O
significantly	O	ADV	O
differ	O	VERB	O
between	O	ADP	O
the	O	DET	O
night	O	NOUN	B
and	O	CCONJ	O
day	O	NOUN	B
time	O	NOUN	O
studies	O	NOUN	O
(	O	PUNCT	O
46	O	NUM	O
+/-	O	CCONJ	O
19	O	NUM	O
%	O	NOUN	O
vs	O	CCONJ	O
34	O	NUM	O
+/-	O	CCONJ	O
10	O	NUM	O
%),	O	ADJ	O
it	O	PRON	O
can	O	AUX	O
be	O	AUX	O
concluded	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
observed	O	VERB	B
sleep	B-Disease	NOUN	B
disturbance	I-Disease	NOUN	I
did	O	AUX	O
not	O	PART	O
interfere	O	VERB	B
with	O	ADP	I
the	O	DET	O
drug	O	NOUN	B
action	O	NOUN	I
per	O	X	O
se	O	X	O
.	O	PUNCT	O


The	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
REM	O	PROPN	B
sleep	O	NOUN	I
was	O	AUX	O
shown	O	VERB	O
not	O	PART	O
to	O	PART	O
be	O	AUX	O
a	O	DET	O
determining	O	VERB	O
factor	O	NOUN	B
either	O	CCONJ	O
for	O	ADP	O
secretory	O	ADJ	B
pulse	O	NOUN	B
amplitude	O	NOUN	I
and	O	CCONJ	O
frequency	O	NOUN	B
,	O	PUNCT	O
as	O	ADP	O
,	O	PUNCT	O
for	O	ADP	O
both	O	DET	O
,	O	PUNCT	O
mean	O	ADJ	O
nocturnal	O	ADJ	B
values	O	NOUN	O
were	O	AUX	O
similar	O	ADJ	O
with	O	ADP	O
and	O	CCONJ	O
without	O	ADP	O
prior	O	ADJ	O
clomipramine	B-Chemical	NOUN	B


Angioedema	B-Disease	NOUN	B
following	O	VERB	O
the	O	DET	O
intravenous	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
metoprolol	B-Chemical	NOUN	B
.	O	PUNCT	O


Her	O	PRON	O
medical	O	ADJ	B
history	O	NOUN	I
included	O	VERB	O
coronary	B-Disease	ADJ	B
artery	I-Disease	NOUN	I
disease	I-Disease	NOUN	I
with	O	ADP	O
previous	O	ADJ	O
myocardial	B-Disease	ADJ	B
infarctions	I-Disease	NOUN	I
,	O	PUNCT	O
hypertension	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
diabetes	B-Disease	NOUN	B
mellitus	I-Disease	NOUN	I
.	O	PUNCT	O


During	O	ADP	O
the	O	DET	O
first	O	ADJ	O
day	O	NOUN	B
of	O	ADP	O
hospitalization	O	NOUN	B
(	O	PUNCT	O
while	O	SCONJ	O
intubated	O	VERB	B
),	O	PUNCT	O
intravenous	O	ADJ	B
metoprolol	B-Chemical	NOUN	B
was	O	AUX	O
given	O	VERB	O
,	O	PUNCT	O
resulting	O	VERB	O
in	O	ADP	O
severe	O	ADJ	B
angioedema	B-Disease	NOUN	B
.	O	PUNCT	O


Effect	O	NOUN	B
of	O	ADP	O
coniine	B-Chemical	NOUN	B
on	O	ADP	O
the	O	DET	O
developing	O	VERB	O
chick	O	NOUN	B
embryo	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
coniine	B-Chemical	NOUN	B
has	O	AUX	O
failed	O	VERB	B
to	O	PART	O
produce	O	VERB	O
arthrogryposis	B-Disease	NOUN	B
in	O	ADP	O
rats	O	NOUN	B
or	O	CCONJ	O
mice	O	NOUN	B
and	O	CCONJ	O
is	O	AUX	O
only	O	ADV	O
weakly	O	ADJ	O
teratogenic	O	ADJ	B
in	O	ADP	O
rabbits	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
purpose	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
evaluate	O	VERB	B
and	O	CCONJ	O
compare	O	VERB	B
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
coniine	B-Chemical	NOUN	B
and	O	CCONJ	O
nicotine	B-Chemical	NOUN	B
in	O	ADP	O
the	O	DET	O
developing	O	VERB	O
chick	O	NOUN	B
.	O	PUNCT	O


Both	O	DET	O
compounds	O	NOUN	B
caused	O	VERB	O
deformations	B-Disease	NOUN	B
and	O	CCONJ	O
lethality	O	NOUN	B
in	O	ADP	O
a	O	DET	O
dose	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
manner	O	NOUN	O
.	O	PUNCT	O


All	O	DET	O
concentrations	O	NOUN	B
of	O	ADP	O
nicotine	B-Chemical	NOUN	B
sulfate	O	NOUN	B
caused	O	VERB	O
some	O	DET	O
lethality	O	NOUN	B
but	O	CCONJ	O
a	O	DET	O
no	O	DET	O
effect	O	NOUN	O
level	O	NOUN	B
for	O	ADP	O
coniine	B-Chemical	NOUN	B
lethality	O	NOUN	B
was	O	AUX	O
0	O	NUM	O
.	O	PUNCT	O


No	O	DET	O
histopathological	O	ADJ	B
alterations	O	NOUN	B
or	O	CCONJ	O
differences	O	NOUN	B
in	O	ADP	O
bone	O	NOUN	B
formation	O	NOUN	I
were	O	AUX	O
seen	O	VERB	O
in	O	ADP	O
the	O	DET	O
limbs	O	NOUN	B
or	O	CCONJ	O
toes	O	NOUN	B
of	O	ADP	O
any	O	DET	O
chicks	O	NOUN	B
from	O	ADP	O
any	O	DET	O
group	O	NOUN	B
;	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
extensive	O	ADJ	O
cranial	B-Disease	ADJ	B
hemorrhage	I-Disease	NOUN	I
occurred	O	VERB	O
in	O	ADP	O
all	O	DET	O
nicotine	B-Chemical	NOUN	B
sulfate	O	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
chicks	O	NOUN	B
.	O	PUNCT	O


67	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
time	O	NOUN	B
,	O	PUNCT	O
while	O	SCONJ	O
coniine	B-Chemical	NOUN	B
-	O	PUNCT	O
treated	O	VERB	B
chicks	O	NOUN	B
were	O	AUX	O
only	O	ADV	O
moving	O	VERB	B
8	O	NUM	O
.	O	PUNCT	O


Epidural	O	ADJ	B
blood	O	NOUN	I
flow	O	NOUN	I
during	O	ADP	O
prostaglandin	B-Chemical	NOUN	B
E1	I-Chemical	NOUN	I
or	O	CCONJ	O
trimethaphan	B-Chemical	NOUN	B
induced	O	VERB	B
hypotension	B-Disease	NOUN	B
.	O	PUNCT	O


min	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	O
of	O	ADP	O
PGE1	B-Chemical	NOUN	B
(	O	PUNCT	O
15	O	NUM	O
patients	O	NOUN	B
),	O	PUNCT	O
or	O	CCONJ	O
10	O	NUM	O
micrograms	O	NOUN	B
.	O	PUNCT	O


After	O	ADP	O
starting	O	VERB	O
PGE1	B-Chemical	NOUN	B
or	O	CCONJ	O
TMP	B-Chemical	NOUN	B
,	O	PUNCT	O
MAP	O	NOUN	B
and	O	CCONJ	O
rate	O	NOUN	B
pressure	O	NOUN	I
product	O	NOUN	I
(	O	PUNCT	O
RPP	O	NOUN	B
)	O	PUNCT	O
decreased	O	VERB	B
significantly	O	ADV	O
compared	O	VERB	O
with	O	ADP	O
preinfusion	O	NOUN	B
values	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


01	O	NUM	O
),	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
degree	O	NOUN	B
of	O	ADP	O
hypotension	B-Disease	NOUN	B
due	O	ADJ	O
to	O	PART	O
PGE1	B-Chemical	NOUN	B
remained	O	VERB	O
constant	O	ADJ	B
until	O	ADP	O
60	O	NUM	O
min	O	NOUN	O
after	O	ADP	O
its	O	PRON	O
discontinuation	O	NOUN	B
.	O	PUNCT	O


Immunohistochemical	O	ADJ	B
studies	O	NOUN	I
with	O	ADP	O
antibodies	O	NOUN	B
to	O	PART	O
neurofilament	O	ADJ	B
proteins	O	NOUN	I
on	O	ADP	O
axonal	B-Disease	ADJ	B
damage	I-Disease	NOUN	I
in	O	ADP	O
experimental	O	ADJ	B
focal	O	ADJ	I
lesions	O	NOUN	I
in	O	ADP	O
rat	O	NOUN	B
.	O	PUNCT	O


Focal	O	ADJ	B
injury	B-Disease	NOUN	I
in	I-Disease	ADP	O
the	I-Disease	DET	O
cortex	I-Disease	NOUN	B
was	O	AUX	O
produced	O	VERB	O
by	O	ADP	O
infusion	O	NOUN	B
of	O	ADP	O
lactate	B-Chemical	NOUN	B
at	O	ADP	O
acid	O	NOUN	B
pH	O	NOUN	I
or	O	CCONJ	O
by	O	ADP	O
stab	O	NOUN	B
caused	O	VERB	O
by	O	ADP	O
needle	O	NOUN	B
insertion	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
immunohistochemical	O	ADJ	B
changes	O	NOUN	B
of	O	ADP	O
NFs	O	NOUN	B
can	O	AUX	O
serve	O	VERB	O
as	O	ADP	O
a	O	DET	O
marker	O	NOUN	B
for	O	ADP	O
axonal	B-Disease	ADJ	B
damage	I-Disease	NOUN	O
in	O	ADP	O
various	O	ADJ	O
experimental	O	ADJ	B
traumatic	B-Disease	ADJ	B


Increase	O	NOUN	B
of	O	ADP	O
Parkinson	B-Disease	PROPN	B
disability	I-Disease	NOUN	I
after	O	ADP	O
fluoxetine	B-Chemical	NOUN	B
medication	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
possibility	O	NOUN	O
of	O	ADP	O
a	O	DET	O
clinically	O	ADV	B
relevant	O	ADJ	O
dopamine	B-Chemical	NOUN	B
-	O	PUNCT	O
antagonistic	O	ADJ	B
capacity	O	NOUN	B
of	O	ADP	O
fluoxetine	B-Chemical	NOUN	B
in	O	ADP	O
Parkinson's	B-Disease	ADJ	O
disease	I-Disease	NOUN	B


Through	O	ADP	O
30	O	NUM	O
years	O	NOUN	B
of	O	ADP	O
widespread	O	ADJ	B
use	O	NOUN	O
,	O	PUNCT	O
acetaminophen	B-Chemical	NOUN	B
has	O	AUX	O
been	O	AUX	O
shown	O	VERB	O
to	O	PART	O
be	O	AUX	O
a	O	DET	O
remarkably	O	ADV	O
safe	O	ADJ	O
medication	O	NOUN	B
in	O	ADP	O
therapeutic	O	ADJ	B
dosages	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
potential	O	NOUN	B
for	O	ADP	O
acetaminophen	B-Chemical	NOUN	B
to	O	PART	O
produce	O	VERB	O
cardiovascular	B-Disease	ADJ	B
toxicities	I-Disease	NOUN	B
is	O	AUX	O
very	O	ADV	O
low	O	ADJ	O
.	O	PUNCT	O


This	O	DET	O
article	O	NOUN	B
describes	O	VERB	O
two	O	NUM	O
critically	B-Disease	ADV	B
ill	I-Disease	ADJ	I
patients	O	NOUN	B
in	O	ADP	O
whom	O	PRON	O
transient	O	ADJ	B
episodes	O	NOUN	I
of	O	ADP	O
hypotension	B-Disease	NOUN	B
reproducibly	O	ADV	B
developed	O	VERB	O
after	O	ADP	O
administration	O	NOUN	B
of	O	ADP	O
acetaminophen	B-Chemical	NOUN	B
.	O	PUNCT	O


Other	O	ADJ	O
symptoms	O	NOUN	B
of	O	ADP	O
allergic	B-Disease	ADJ	B
reactions	I-Disease	NOUN	I
were	O	AUX	O
not	O	PART	O
clinically	O	ADV	O
detectable	O	ADJ	B
.	O	PUNCT	O


Acute	O	ADJ	B
hepatitis	B-Disease	NOUN	I
,	O	PUNCT	O
autoimmune	B-Disease	ADJ	B
hemolytic	I-Disease	ADJ	I
anemia	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
erythroblastocytopenia	B-Disease	NOUN	B
induced	O	VERB	B
by	O	ADP	O
ceftriaxone	B-Chemical	NOUN	B
.	O	PUNCT	O


Although	O	SCONJ	O
the	O	DET	O
transaminases	O	NOUN	B
gradually	O	ADV	O
returned	O	VERB	O
to	O	PART	O
baseline	O	NOUN	B
after	O	ADP	O
withholding	O	VERB	B
the	O	DET	O
beta	B-Chemical	NOUN	B
lactam	I-Chemical	NOUN	I
antibiotic	O	NOUN	B
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
a	O	DET	O
gradual	O	ADJ	O
increase	O	NOUN	B
in	O	ADP	O
serum	O	NOUN	B
bilirubin	B-Chemical	NOUN	B
and	O	CCONJ	O
a	O	DET	O
decrease	O	NOUN	B
in	O	ADP	O
hemoglobin	O	NOUN	B
concentration	O	NOUN	I
caused	O	VERB	O
by	O	ADP	O
an	O	DET	O
autoimmune	B-Disease	ADJ	B
hemolytic	I-Disease	ADJ	I
anemia	I-Disease	NOUN	I
and	O	CCONJ	O
erythroblastocytopenia	B-Disease	NOUN	B
.	O	PUNCT	O


Despite	O	SCONJ	O
the	O	DET	O
widespread	O	ADJ	B
use	O	NOUN	O
of	O	ADP	O
these	O	DET	O
agents	O	NOUN	B
this	O	DET	O
triad	O	NOUN	O
of	O	ADP	O
side	O	NOUN	B
effects	O	NOUN	I
has	O	AUX	O
not	O	PART	O
previously	O	ADV	O
been	O	AUX	O
reported	O	VERB	O
in	O	ADP	O
connection	O	NOUN	B
with	O	ADP	O
beta	B-Chemical	NOUN	B
lactam	I-Chemical	NOUN	I


Conventional	O	ADJ	B
agents	O	NOUN	I
are	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
unwanted	O	ADJ	O
central	O	ADJ	B
nervous	O	ADJ	I
system	O	NOUN	I
effects	O	NOUN	I
,	O	PUNCT	O
including	O	VERB	O
extrapyramidal	B-Disease	ADJ	B
symptoms	I-Disease	NOUN	I
(	O	PUNCT	O
EPS	B-Disease	NOUN	B
),	O	PUNCT	O
tardive	B-Disease	NOUN	B
dyskinesia	I-Disease	NOUN	I
,	O	PUNCT	O
sedation	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
possible	O	ADJ	O
impairment	O	NOUN	B
of	O	ADP	O
some	O	DET	O
cognitive	O	ADJ	B
measures	O	NOUN	I
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
cardiac	O	ADJ	B
effects	O	NOUN	I
,	O	PUNCT	O
orthostatic	B-Disease	ADJ	B
hypotension	I-Disease	NOUN	B
,	O	PUNCT	O
hepatic	O	ADJ	B
changes	O	NOUN	I
,	O	PUNCT	O
anticholinergic	O	ADJ	B
side	O	NOUN	B
effects	O	NOUN	I
,	O	PUNCT	O
sexual	B-Disease	ADJ	B
dysfunction	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
weight	B-Disease	NOUN	B
gain	I-Disease	NOUN	I
.	O	PUNCT	O


Effects	O	NOUN	B
of	O	ADP	O
tetrandrine	B-Chemical	NOUN	B
and	O	CCONJ	O
fangchinoline	B-Chemical	NOUN	B
on	O	ADP	O
experimental	O	ADJ	B
thrombosis	B-Disease	NOUN	I
in	O	ADP	O
mice	O	NOUN	B
and	O	CCONJ	O
human	O	ADJ	B
platelet	B-Disease	NOUN	O
aggregation	I-Disease	NOUN	O
.	O	PUNCT	O


p	O	NOUN	O
.)	O	NUM	O
of	O	ADP	O
TET	B-Chemical	NOUN	B
and	O	CCONJ	O
FAN	B-Chemical	NOUN	B
in	O	ADP	O
mice	O	NOUN	B
showed	O	VERB	O
the	O	DET	O
inhibition	O	NOUN	B
of	O	ADP	O
thrombosis	B-Disease	NOUN	B
by	O	ADP	O
55	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
35	O	NUM	O
%,	O	ADJ	O
respectively	O	ADV	O
,	O	PUNCT	O
while	O	SCONJ	O
acetylsalicylic	B-Chemical	ADJ	B
acid	I-Chemical	NOUN	I
(	O	PUNCT	O
ASA	B-Chemical	NOUN	B
,	O	PUNCT	O
50	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
,	O	PUNCT	O
i	O	X	O
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
neither	O	CCONJ	O
TET	B-Chemical	NOUN	B
nor	O	CCONJ	O
FAN	B-Chemical	PROPN	B
showed	O	VERB	O
any	O	DET	O
anticoagulation	O	NOUN	B
activities	O	NOUN	I
in	O	ADP	O
the	O	DET	O
measurement	O	NOUN	B
of	O	ADP	O
the	O	DET	O
activated	O	VERB	B
partial	O	ADJ	I
thromboplastin	O	NOUN	I
time	O	NOUN	I
(	O	PUNCT	O
APTT	O	NOUN	B
),	O	PUNCT	O
prothrombin	O	NOUN	B
time	O	NOUN	I
(	O	PUNCT	O
PT	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
thrombin	O	NOUN	B
time	O	NOUN	I
(	O	PUNCT	O
TT	O	NOUN	B
)	O	PUNCT	O
using	O	VERB	O
human	O	ADJ	B
-	O	PUNCT	O
citrated	O	VERB	B
plasma	O	NOUN	B
.	O	PUNCT	O


Gemcitabine	B-Chemical	NOUN	B
plus	O	CCONJ	O
vinorelbine	B-Chemical	NOUN	B
in	O	ADP	O
nonsmall	B-Disease	NOUN	B
cell	I-Disease	NOUN	I
lung	I-Disease	NOUN	I
carcinoma	I-Disease	NOUN	I
patients	O	NOUN	B
age	O	NOUN	B
70	O	NUM	O
years	O	NOUN	B
or	O	CCONJ	O
older	O	ADJ	B
or	O	CCONJ	O
patients	O	NOUN	B
who	O	PRON	O
cannot	O	VERB	O
receive	O	VERB	O
cisplatin	B-Chemical	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
current	O	ADJ	O
study	O	NOUN	B
the	O	DET	O
efficacy	O	NOUN	B
and	O	CCONJ	O
toxicity	B-Disease	NOUN	B
of	O	ADP	O
the	O	DET	O
combination	O	NOUN	B
of	O	ADP	O
GEM	B-Chemical	NOUN	B
and	O	CCONJ	O
VNB	B-Chemical	NOUN	B
in	O	ADP	O
elderly	O	ADJ	B
patients	O	NOUN	B
with	O	ADP	O
advanced	O	ADJ	B
NSCLC	B-Disease	NOUN	B
or	O	CCONJ	O
those	O	DET	O
with	O	ADP	O
some	O	DET	O
contraindication	O	NOUN	B
to	O	ADP	O
receiving	O	VERB	O
cisplatin	B-Chemical	NOUN	B
were	O	AUX	O
assessed	O	VERB	B
.	O	PUNCT	O


All	O	DET	O
patients	O	NOUN	B
were	O	AUX	O
evaluable	O	ADJ	O
for	O	ADP	O
response	O	NOUN	B
and	O	CCONJ	O
toxicity	B-Disease	NOUN	B
.	O	PUNCT	O


Treatment	O	NOUN	B
was	O	AUX	O
comprised	O	VERB	O
of	O	ADP	O
VNB	B-Chemical	NOUN	B
,	O	PUNCT	O
25	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m	O	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
),	O	PUNCT	O
plus	O	CCONJ	O
GEM	B-Chemical	NOUN	B
,	O	PUNCT	O
1000	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
m	O	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
),	O	PUNCT	O
both	O	DET	O
on	O	ADP	O
Days	O	NOUN	O
1	O	NUM	O
,	O	PUNCT	O
8	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
15	O	NUM	O
every	O	DET	O
28	O	NUM	O
days	O	NOUN	B
.	O	PUNCT	O


Six	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
12	O	NUM	O
%)	O	NOUN	O
had	O	AUX	O
World	O	PROPN	B
Health	O	PROPN	I
Organization	O	PROPN	I
Grade	O	PROPN	I
3	O	NUM	I
-	O	SYM	O
4	O	NUM	O
neutropenia	B-Disease	NOUN	B
,	O	PUNCT	O
2	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
4	O	NUM	O
%)	O	NOUN	O
had	O	AUX	O
Grade	O	PROPN	B
3	O	NUM	I
-	O	SYM	O
4	O	NUM	O
thrombocytopenia	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
2	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
4	O	NUM	O
%)	O	NOUN	O
had	O	AUX	O
Grade	O	PROPN	B
3	O	NUM	I
neurotoxicity	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
median	O	ADJ	B
age	O	NOUN	B
of	O	ADP	O
those	O	DET	O
patients	O	NOUN	B
developing	O	VERB	O
Grade	O	NOUN	B
3	O	NUM	I
-	O	SYM	O
4	O	NUM	O
neutropenia	B-Disease	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
higher	O	ADJ	O
than	O	ADP	O
that	O	DET	O
of	O	ADP	O
the	O	DET	O
remaining	O	VERB	O
patients	O	NOUN	B
(	O	PUNCT	O
75	O	NUM	O
years	O	NOUN	B
vs	O	ADV	O
.	O	PUNCT	O


New	O	ADJ	B
chemotherapy	O	NOUN	I
combinations	O	NOUN	B
with	O	ADP	O
higher	O	ADJ	O
activity	O	NOUN	B
and	O	CCONJ	O
lower	O	ADJ	B
toxicity	B-Disease	NOUN	B
are	O	AUX	O
needed	O	VERB	O
for	O	ADP	O
elderly	O	ADJ	B
patients	O	NOUN	B
with	O	ADP	O
advanced	O	ADJ	B
NSCLC	B-Disease	NOUN	B


Warfarin	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
artery	B-Disease	NOUN	B
calcification	I-Disease	NOUN	I
is	O	AUX	O
accelerated	O	VERB	B
by	O	ADP	O
growth	O	NOUN	B
and	O	CCONJ	O
vitamin	B-Chemical	NOUN	B
D	I-Chemical	NOUN	I
.	O	PUNCT	O


The	O	DET	O
first	O	ADJ	O
series	O	NOUN	O
of	O	ADP	O
experiments	O	NOUN	B
examined	O	VERB	B
the	O	DET	O
influence	O	NOUN	B
of	O	ADP	O
age	O	NOUN	B
and	O	CCONJ	O
growth	O	NOUN	B
status	O	NOUN	I
on	O	ADP	O
artery	B-Disease	NOUN	B
calcification	I-Disease	NOUN	I
in	O	ADP	O
Warfarin	B-Chemical	PROPN	B
-	O	PUNCT	O
treated	O	VERB	B
rats	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
no	O	DET	O
artery	B-Disease	NOUN	B
calcification	I-Disease	NOUN	I
could	O	AUX	O
be	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
10	O	NUM	O
-	O	PUNCT	O
month	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
adult	O	ADJ	B
rats	O	NOUN	B
even	O	ADV	O
after	O	ADP	O
4	O	NUM	O
weeks	O	NOUN	B
of	O	ADP	O
Warfarin	B-Chemical	NOUN	B
treatment	O	NOUN	B
.	O	PUNCT	O


Concurrent	O	ADJ	B
treatment	O	NOUN	B
of	O	ADP	O
both	O	CCONJ	O
dietary	O	ADJ	B
groups	O	NOUN	I
with	O	ADP	O
Warfarin	B-Chemical	NOUN	B
produced	O	VERB	O
massive	O	ADJ	B
focal	O	ADJ	B
calcification	B-Disease	NOUN	I
of	I-Disease	ADP	O
the	I-Disease	DET	O
artery	I-Disease	NOUN	B
media	O	NOUN	I
in	O	ADP	O
the	O	DET	O
ad	O	NOUN	B
libitum	O	NOUN	I
-	O	PUNCT	O
fed	O	VERB	B
rats	O	NOUN	B
but	O	CCONJ	O
no	O	DET	O
detectable	O	ADJ	O
artery	B-Disease	NOUN	B
calcification	I-Disease	NOUN	I
in	O	ADP	O
the	O	DET	O
restricted	O	ADJ	B
-	O	PUNCT	O
diet	O	NOUN	B
,	O	PUNCT	O
growth	O	NOUN	B
-	O	PUNCT	O
inhibited	O	VERB	B
group	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
observation	O	NOUN	B
suggests	O	VERB	O
that	O	SCONJ	O
increased	O	VERB	B
susceptibility	O	NOUN	B
to	O	ADP	O
Warfarin	B-Chemical	PROPN	B
-	O	PUNCT	O
induced	O	VERB	B
artery	B-Disease	NOUN	B
calcification	I-Disease	NOUN	I
could	O	AUX	O
be	O	AUX	O
related	O	ADJ	O
to	O	PART	O
higher	O	ADJ	O
serum	O	NOUN	B
phosphate	B-Chemical	NOUN	I
levels	O	NOUN	I
.	O	PUNCT	O


High	O	ADJ	B
doses	O	NOUN	I
of	O	ADP	O
vitamin	B-Chemical	NOUN	B
D	I-Chemical	NOUN	I
are	O	AUX	O
known	O	VERB	O
to	O	PART	O
cause	O	VERB	O
calcification	B-Disease	NOUN	B
of	I-Disease	ADP	O
the	I-Disease	DET	O
artery	I-Disease	NOUN	B
media	O	NOUN	I
in	O	ADP	O
as	O	ADV	O
little	O	ADJ	O
as	O	ADP	O
3	O	NUM	O
to	O	PART	O
4	O	NUM	O
days	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
current	O	ADJ	O
study	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
investigated	O	VERB	B
the	O	DET	O
synergy	O	NOUN	B
between	O	ADP	O
these	O	DET	O
2	O	NUM	O
treatments	O	NOUN	B
and	O	CCONJ	O
found	O	VERB	O
that	O	SCONJ	O
concurrent	O	ADJ	B
Warfarin	B-Chemical	PROPN	B
administration	O	NOUN	O
dramatically	O	ADV	O
increased	O	VERB	B
the	O	DET	O
extent	O	NOUN	O
of	O	ADP	O
calcification	B-Disease	NOUN	B
in	O	ADP	O
the	O	DET	O
media	O	NOUN	B
of	O	ADP	O
vitamin	B-Chemical	NOUN	B
D	I-Chemical	NOUN	I
-	O	PUNCT	O
treated	O	VERB	B
rats	O	NOUN	B
at	O	ADP	O
3	O	NUM	O
and	O	CCONJ	O
4	O	NUM	O
days	O	NOUN	B
.	O	PUNCT	O


Because	O	SCONJ	O
Warfarin	B-Chemical	NOUN	B
treatment	O	NOUN	B
had	O	AUX	O
no	O	DET	B
effect	O	NOUN	I
on	O	ADP	O
the	O	DET	O
elevation	O	NOUN	B
in	O	ADP	O
serum	O	NOUN	B
calcium	B-Chemical	NOUN	I
produced	O	VERB	O
by	O	ADP	O
vitamin	B-Chemical	NOUN	B
D	I-Chemical	NOUN	I
,	O	PUNCT	O
the	O	DET	O
synergy	O	NOUN	B
between	O	ADP	O
Warfarin	B-Chemical	NOUN	B
and	O	CCONJ	O
vitamin	B-Chemical	NOUN	B
D	I-Chemical	NOUN	I
is	O	AUX	O
probably	O	ADV	O
best	O	ADV	O
explained	O	VERB	O
by	O	ADP	O
the	O	DET	O
hypothesis	O	NOUN	B
that	O	SCONJ	O
Warfarin	B-Chemical	NOUN	B
inhibits	O	VERB	B
the	O	DET	O
activity	O	NOUN	B
of	O	ADP	O
matrix	O	NOUN	B
Gla	O	NOUN	I
protein	O	NOUN	I
as	O	ADP	O
a	O	DET	O
calcification	B-Disease	NOUN	B
inhibitor	O	NOUN	B
.	O	PUNCT	O


Patients	O	NOUN	B
who	O	PRON	O
experienced	O	VERB	O
a	O	DET	O
manic	B-Disease	ADJ	B
or	O	CCONJ	O
hypomanic	B-Disease	ADJ	B
switch	O	NOUN	B
were	O	AUX	O
compared	O	VERB	B
with	O	ADP	O
those	O	DET	O
who	O	PRON	O
did	O	AUX	O
not	O	PART	O
on	O	ADP	O
several	O	ADJ	O
variables	O	NOUN	B
including	O	VERB	O
age	O	NOUN	B
,	O	PUNCT	O
sex	O	NOUN	B
,	O	PUNCT	O
diagnosis	O	NOUN	B
(	O	PUNCT	O
DSM-IV	B-Disease	NOUN	B
bipolar	I-Disease	NOUN	I
I	I-Disease	NUM	I
vs	O	ADV	O
.	O	PUNCT	O


antidepressant	B-Chemical	ADJ	B
drugs	O	NOUN	B
and	O	CCONJ	O
,	O	PUNCT	O
more	O	ADV	O
particularly	O	ADV	O
,	O	PUNCT	O
selective	O	ADJ	O
serotonin	B-Chemical	NOUN	B
reuptake	I-Chemical	NOUN	I
inhibitors	I-Chemical	NOUN	I
[	O	PUNCT	O
SSRIs	B-Chemical	PROPN	B
]),	O	ADJ	O
use	O	NOUN	O
and	O	CCONJ	O
type	O	NOUN	O
of	O	ADP	O
mood	O	NOUN	B
stabilizers	O	NOUN	I
(	O	PUNCT	O
lithium	B-Chemical	NOUN	B
vs	O	CCONJ	O
.	O	PUNCT	O


bipolar	B-Disease	NOUN	B
II	I-Disease	NUM	I
),	O	PUNCT	O
and	O	CCONJ	O
additional	O	ADJ	B
treatment	O	NOUN	B
did	O	AUX	O
not	O	PART	O
affect	O	VERB	O
the	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
switching	O	NOUN	B
.	O	PUNCT	O


Molecularly	O	NOUN	B
,	O	PUNCT	O
ANF	O	NOUN	B
mRNA	O	NOUN	B
increased	O	VERB	B
250	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
SERCA2	O	NOUN	B
mRNA	O	NOUN	B
decreased	O	VERB	B
57	O	NUM	O
%.	O	NOUN	B
Biochemically	O	ADV	B
,	O	PUNCT	O
LA	B-Chemical	PROPN	B
was	O	AUX	O
elevated	O	ADJ	B
(	O	PUNCT	O
8	O	NUM	O
.	O	PUNCT	O


e	O	X	O
.,	O	NOUN	O
desogestrel	B-Chemical	NOUN	B
or	O	CCONJ	O
gestodene	B-Chemical	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
second	O	ADJ	B
-	O	PUNCT	O
generation	O	NOUN	B
(	O	PUNCT	O
i	O	X	O
.	O	PUNCT	O


1	O	X	O
)	O	PUNCT	O
among	O	ADP	O
women	O	NOUN	B
who	O	PRON	O
used	O	VERB	O
second	O	ADJ	B
-	O	PUNCT	O
generation	O	NOUN	B
oral	B-Chemical	ADJ	B
contraceptives	I-Chemical	NOUN	I
and	O	CCONJ	O
1	O	NUM	O
.	O	PUNCT	O


Among	O	ADP	O
women	O	NOUN	B
who	O	PRON	O
used	O	VERB	O
oral	B-Chemical	ADJ	B
contraceptives	I-Chemical	NOUN	I
,	O	PUNCT	O
the	O	DET	O
odds	O	NOUN	B
ratio	O	NOUN	I
was	O	AUX	O
2	O	NUM	O
.	O	PUNCT	O


Male	O	NOUN	B
Wistar	O	PROPN	B
rats	O	NOUN	I
were	O	AUX	O
implanted	O	VERB	B
bilaterally	O	ADV	O
with	O	ADP	O
cannulae	O	NOUN	B
into	O	ADP	O
the	O	DET	O
accumbens	O	NOUN	B
shell	O	NOUN	B
or	O	CCONJ	O
core	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
then	O	ADV	O
were	O	AUX	O
locally	O	ADV	B
injected	O	VERB	I
with	O	ADP	O
GR	B-Chemical	NOUN	B
55562	I-Chemical	NUM	O
(	O	PUNCT	O
an	O	DET	O
antagonist	O	NOUN	B
of	O	ADP	O
5	O	NUM	O
-	O	PUNCT	O
HT1B	O	NOUN	B
receptors	O	NOUN	I
)	O	PUNCT	O
or	O	CCONJ	O
CP	B-Chemical	NOUN	B
93129	I-Chemical	NUM	O
(	O	PUNCT	O
an	O	DET	O
agonist	O	NOUN	B
of	O	ADP	O
5	O	NUM	O
-	O	PUNCT	O
HT1B	O	NOUN	B
receptors	O	NOUN	I
).	O	PUNCT	B
Given	O	VERB	O
alone	O	ADV	O
to	O	PART	O
any	O	DET	O
accumbal	O	NOUN	B
subregion	O	NOUN	B
,	O	PUNCT	O
GR	B-Chemical	NOUN	B
55562	I-Chemical	NUM	O
(	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O


Systemic	O	ADJ	B
cocaine	B-Chemical	NOUN	I
(	O	PUNCT	O
10	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
kg	O	NOUN	B
)	O	PUNCT	O
significantly	O	ADV	O
increased	O	VERB	B
the	O	DET	O
locomotor	O	NOUN	B
activity	O	NOUN	I
of	O	ADP	O
rats	O	NOUN	B
.	O	PUNCT	O


Such	O	ADJ	O
attenuation	O	NOUN	B
was	O	AUX	O
not	O	PART	O
found	O	VERB	O
in	O	ADP	O
animals	O	NOUN	B
which	O	DET	O
had	O	AUX	O
been	O	AUX	O
injected	O	VERB	B
with	O	ADP	O
GR	B-Chemical	NOUN	B
55562	I-Chemical	NUM	O
into	O	ADP	O
the	O	DET	O
accumbens	O	NOUN	B
core	O	NOUN	B
.	O	PUNCT	O


1	O	NUM	O
-	O	SYM	O
10	O	NUM	O
microg	O	NOUN	B
/	O	SYM	O
side	O	NOUN	B
)	O	PUNCT	O
enhanced	O	VERB	B
the	O	DET	O
locomotor	O	NOUN	B
response	O	NOUN	I
to	O	PART	O
cocaine	B-Chemical	NOUN	B
;	O	PUNCT	O
the	O	DET	O
maximum	O	ADJ	B
effect	O	NOUN	B
being	O	AUX	O
observed	O	VERB	B
after	O	ADP	O
10	O	NUM	O
microg	O	NOUN	B
/	O	SYM	O
side	O	NOUN	B
of	O	ADP	O
the	O	DET	O
agonist	O	NOUN	B
.	O	PUNCT	O


Hepatitis	B-Disease	NOUN	B
may	O	AUX	O
develop	O	VERB	O
weeks	O	NOUN	B
after	O	ADP	O
discontinuation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
drug	O	NOUN	B
and	O	CCONJ	O
may	O	AUX	O
run	O	VERB	O
a	O	DET	O
prolonged	O	ADJ	B
course	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
complete	O	ADJ	O
remission	O	NOUN	B
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
all	O	DET	O
reported	O	VERB	O
cases	O	NOUN	B
.	O	PUNCT	O


Fifteen	O	NUM	O
female	O	ADJ	B
migraineurs	B-Disease	NOUN	I
(without	I-Disease	ADP	O
aura)	I-Disease	ADJ	B
and	O	CCONJ	O
eight	O	NUM	O
controls	O	NOUN	B
participated	O	VERB	O
in	O	ADP	O
the	O	DET	O
study	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
both	O	DET	O
change	O	NOUN	B
and	O	CCONJ	O
peak	O	NOUN	B
,	O	PUNCT	O
showed	O	VERB	O
significant	O	ADJ	O
positive	O	ADJ	B
correlations	O	NOUN	B
with	O	ADP	O
migraine	B-Disease	NOUN	B
headache	B-Disease	NOUN	I
intensity	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O


The	O	DET	O
patient	O	NOUN	B
was	O	AUX	O
asymptomatic	O	ADJ	B
and	O	CCONJ	O
the	O	DET	O
aneurysm	B-Disease	NOUN	B
was	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
a	O	DET	O
routine	O	ADJ	O
control	O	NOUN	B
.	O	PUNCT	O


